KSN 2019

SEOUL, KOREA MAY 23 - 26

The 39th Annual Meeting of the Korean Society of Nephrology

Seoul Dragon City, Seoul, Korea

"Peaceful Kidneys, Save Lives"

THE KOREAN SOCIETY OF NEPHROLOGY

Platinum Sponsors

FRESENIUS MEDICAL CARE · Baxter · YUHAN

Gold Sponsors

HANDOK · Otsuka · KYOWA KIRIN · SK chemicals · JW Pharmaceutical · Roche · BORYUNG · CJ HealthCare

Endorsed by

ISN

PROGRAM BOOK

Patients with aHUS can be at continuous risk of the life-threatening consequences of unpredictable complement-mediated TMA[1,2]

Chronic, uncontrolled complement activity in aHUS leads to ongoing endothelial injury, organ damage, and sudden death[2,3]



SOLIRIS®
(eculizumab)

References: 1. Laurence J. *Clin Adv Hematol Oncol*. 2016;14(suppl 11):1–15. 2. Legendre CM, et al. *N Engl J Med*. 2013;368:2169–2181. 3. Noris M, et al. *Nat Rev Nephrol*. 2012;8:622–633.

Selected prescribing information

전문의약품

[제품명] 솔리리스주 **[조성]** 1바이알(30mL)중 에쿨리주맙 300mg **[효능 · 효과] 1) 발작성 야간 혈색소뇨증(PNH : Paroxysmal Nocturnal Hemoglobinuria)** 용혈을 감소시키기 위한 발작성 야간 혈색소뇨증(PNH) 환자의 치료. 수혈 이력과 관계없이, 높은 질병 활성을 의미하는 임상 증상이 있는 환자의 용혈에 임상적 이익이 확립되었다. **2) 비정형 용혈성 요독 증후군(aHUS : atypical Hemolytic Uremic Syndrome)** 보체 매개성 혈전성 미세혈관병증을 억제하기 위한 비정형 용혈성 요독 증후군(aHUS) 환자의 치료 **[용법 · 용량]** 심각한 감염에 대한 위험을 줄이기 위해서 환자들은 최신의 백신 접종 지침(Advisory Committee on Immunization Practices(ACIP) recommendations)에 따라 백신 접종을 해야 한다. (용법 · 용량 4)항 참고) **1) 권장 용법 · 용량 – 발작성 야간 혈색소뇨증(PNH)** – 첫 4주간은 매 7일마다 600 mg을 투여한다. – 네 번째 용량 투여 7일 후에 다섯 번째 용량으로 900 mg를 투여하고, – 그 후부터는 매 14일마다 900 mg를 투여한다. 이 약은 권장 투여량과 일정에 맞게 투여, 혹은 예정된 일정의 2일 전/후로 투여 되어야 한다. **2) 권장 용법 · 용량 – 비정형 용혈성 요독 증후군(aHUS)** 만 18세 이상의 환자일 경우, – 첫 4주간은 매 7일마다 900 mg를 투여한다. – 네 번째 용량 투여 7일 후에 다섯 번째 용량으로 1200 mg를 투여하고, – 그 후부터는 매 14일마다 1200 mg를 투여한다. 이 약은 권장 투여량과 일정에 맞게 투여, 혹은 예정된 일정의 2일 전/후로 투여되어야 한다. PE/PI(혈장 교환 요법(plasma exchange 또는 plasmapheresis), 또는 신선 동결 혈장 투여(fresh frozen plasma infusion))와 같은 부수적 시술을 받는 경우 추가 용량 투여가 필요하다. [사용상의 주의사항] 1. 경고 중대한 수막구균 감염 적응기전으로 인하여 이 약의 사용은 중대한 수막구균 감염(패혈증 그리고/또는 뇌수막염)에 대한 환자의 감수성을 증가시킨다. 이 약의 투여 환자에게서 치명적이고 생명을 위협하는 수막구균 감염이 발생하였다. 수막구균 감염은 어느 혈청군에 의해서도 발생할 수 있지만, 이 약의 투여 환자들은 흔하지 않은 혈청군(X 등)에 의한 질환이 발생할 수 있다. 감염의 위험성을 낮추기 위하여, 이 약의 치료가 지연됨으로 인한 위험성이 수막구균 감염 발생의 위험성보다 큰 경우를 제외하고는 모든 환자들은 반드시 이 약의 투여 시작 최소한 2주 전에 수막구균 백신을 투여 받아야 한다. 만약 접종 받지 않은 환자가 긴급히 이 약의 치료를 받아야 하면, 최대한 빨리 수막구균 백신을 투여 받도록 한다. 수막구균 백신 접종 이후 2주 이내 이 약을 투여할 경우, 수막구균 백신 접종 이후 2주 동안 적절한 예방적 항생요법으로 치료 받아야 한다. 흔한 병원성 수막구균 혈청군을 예방하기 위하여 가능하다면 혈청군 A, C, Y, W135, B에 대한 백신이 권장된다. 환자들은 백신 사용을 위한 최신의 백신 접종 지침(ACIP recommendations)에 따라 백신을 접종 혹은 재접종 받아야 한다. 백신 접종은 보체를 더욱 활성화시킬 수 있다. 결과적으로, PNH 및 aHUS를 포함한 보체 매개 질환을 가진 환자들은 용혈(PNH의 경우)이나 혈전성 미세혈관병증(TMA: aHUS의 경우)과 같은 그들의 기저 질환의 징후 및 증상이 증가하는 경험을 할 수 있다. 따라서, 치침에 따른 백신 접종 이후 질환의 증상에 대해 면밀히 관찰되어야 한다. 백신 접종은 수막구균 감염 위험을 줄일 수 있지만, 완전히 없애지는 않는다. 적절한 항생제 사용에 대한 공식 지침(예: 국내 성인 세균성 수막염의 임상진료지침 권고안 등)을 고려하여야 한다. 수막구균 감염의 초기 징후나 증상이 나타나는지 면밀히 관찰하고, 감염이 의심되면 즉시 검사받아야 한다. 환자는 이러한 징후와 증상 및 즉시 치료를 받는 절차에 대해 안내 받아야 하며, 담당 의사는 빈드시 환자와 이 약의 치료의 위험과 이익을 상의하여야 한다. 수막구균 감염은 초기에 발견하고 치료하지 않으면 급격히 치명적이고 생명을 위협하게 된다. 중대한 수막구균 감염을 치료하는 환자는 이 약의 투여를 중지하도록 한다. **2. 투여금기** 1) 이 약의 주성분, 뮤린 단백질 또는 기타 구성성분에 과민반응이 있는 환자 2) 치료되지 않은 중대한 수막구균(Neisseria meningitidis) 감염 환자 3) 수막구균(Neisseria meningitidis) 백신을 현재 접종하지 않은 환자 또는 백신 접종 이후 2주 동안 적절한 예방적 항생요법으로 치료를 받지 않은 환자(이 약의 치료를 늦추는 것이 수막구균 감염을 일으키는 것보다 중대하지 않은 경우) **3. 신중투여** 1) 기타 전신 감염 적용기전으로 인하여 이 약의 치료는 활성 전신 감염이 있는 환자들에게 주의하여 투여하여야 한다. 이 약은 말단 보체 활성을 차단하므로 환자들은 감염, 특히 Neisseria균 및 피낭성 세균(encapsulated bacteria) 감염에 대한 감수성이 증가할 수 있다. 파종성 임균 감염을 포함하는 N. meningitidis 외의 Neisseria 종에 의한 중대한 감염이 보고되었다. 잠재적인 중대한 감염과 그 증상 및 징후에 대한 인식을 높이기 위하여 환자용 정보 안내서의 정보를 환자에게 제공해야 한다. 임질 예방에 관해 환자에게 조언해야 하고 위험성이 있는 환자는 정기적인 검사를 권고한다. 더욱이, 면역력이 약화된 환자와 호중구 감소 환자에서 아스페르길루스 감염이 발생하였다. 이 약을 투여 받는 소아는 폐렴연쇄상구균(Streptococcus pneumoniae)과 인플루엔자 간균 B형(i-haemophilus influenza type b(Hib))에 의한 감염을 예방하기 위해 최신의 백신 접종 지침에 따라 백신 접종을 받도록 한다. 전신 감염이 있는 환자에게 이 약을 투여할 때는 주의하도록 한다. 에culizumab에 안정되고 유지 요법을 받는 환자에게 추가적인 백신 접종이 필요한 경우, 이 약 투여에 따른 백신 접종 시기를 신중히 고려해야 한다. 2) 실험실적 검사 결과 모니터링 발작성 야간 혈색소뇨증(PNH): PNH 환자의 혈청 LDH(Lactate dehydrogenase)를 포함한 혈관 및 중성을 관찰하여야 한다. 이 약으로 치료 받는 PNH 환자는 LDH 수치를 확인하여 혈관 내 용혈을 관찰하여야 하며, 유지기간 동안 권장 투여일정(14±2일) 내에서 용법 · 용량 조정이 필요할 수 있다(매 12일까지). 비정형 용혈성 요독 증후군(aHUS): 이 약으로 치료 받는 aHUS 환자는 혈소판 수, 혈청 LDH, 혈청 크레아티닌을 측정하여 미세혈관병증 여부를 관찰하여야 하며, 유지기간 동안 권장 투여일정(14±2일) 내에서 용법 · 용량 조정이 필요할 수 있다(매 12일까지). **4. 주요 이상반응** 시판 후 보고 및 PNH, aHUS 임상시험에 참여한 302명의 환자에서 보고된 약물이상반응: 매우 흔하게(≥1/10) – 두통, 흔하게(≥1/100 ~ (1/10) – 수막구균패혈증, 아스페르길루스(Aspergillus) 감염, 세균성 관절염, 상기도감염, 비인두염, 기관지염, 구강 헤르페스, 요도 감염, 바이러스성 감염, 혈소판감소증, 백혈구감소증, 용혈, 아나필락시스 반응, 식욕감퇴, 현기증, 미각이상, 저혈압, 호흡곤란, 기침, 비충혈, 인후두 통증, 콧물, 설사, 구토, 구역, 복부통증, 변비, 소화불량, 발진, 탈모, 소양증, 관절통, 근육통, 근육경련, 뼈 통증, 요통, 목 통증, 사지(팔다리) 통증, 부종, 가슴 불편함, 열, 오한, 피로감, 무력증, 인플루엔자 유사질환, 콩스니함 양성 모든 임상시험에서, 가장 중대한 이상반응은 수막구균 패혈증이었고, 이는 이 약으로 치료받은 환자에서 수막구균 감염증의 흔한 증상이었다. 수막구균 패혈증의 징후와 증상에 대해 환자에게 알리고 즉시 의료 조치 받을 것을 환자에게 권고해야 한다. Neisseria gonorrhoeae, Neisseria sicca / subflava, Neisseria spp unspecified로 인한 패혈증을 포함하여 Neisseria 종의 다른 사례들이 보고되었다. **[제조원]** 알렉시온 **[수입판매원]** (주)한독 **[최종개정일]** 2018-10-01

KR.ECO.19.01.04

ALEXION

(주)한독 서울시 강남구 테헤란로 132 Tel. 02)527–5114 Fax. 02) 527–5001 www.handok.co.kr

HANDOK

Slow ADPKD. Preserve Hope.

Introducing Samsca – The first and only treatment proven to slow cyst progression



Samsca® Tablet ADPKD product information summary [INDICATION] To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease. **[DOSAGE & ADMINISTRATION] Tolvaptan must only be prescribed by physicians who got registered in Risk Management Program to the patients who have agreed and signed on conditions specified in Risk Management Program.** Patient should follow this program. And, to mitigate the risk of significant and/or irreversible liver injury, **blood testing for hepatic transaminases and bilirubin is required prior to initiation of SAMSCA, continuing monthly for 18 months and at regular 3 monthly intervals thereafter.** The initial dose is 60 mg tolvaptan per day as a split-dose regimen of 45 mg + 15 mg (45 mg taken upon waking and prior the morning meal and 15 mg taken 8 hours later). The initial dose is to be titrated upward to a split-dose regimen of 90 mg tolvaptan (60 mg + 30 mg) per day and then to a target split-dose regimen of 120 mg tolvaptan (90 mg + 30 mg) per day, if tolerated, with at least weekly intervals between titrations. Dose titration has to be performed cautiously to ensure that high doses are not poorly tolerated through overly rapid up-titration. Patients may down-titrate to lower doses based on tolerability. Patients have to be maintained on the highest tolerable tolvaptan dose. ※ Samsca® Tablet has an indication for hyponatremia as well. For further information, please refer to the latest prescribing information at www.otsuka.co.kr.

Otsuka
Korea Otsuka Pharm.
Under license of Otsuka pharmaceutical Co.,Ltd

Otsuka Vision Bldg., 226, Yeoksam-ro, Gangnam-gu, Seoul, 06227, Republic of Korea
Tel +82-2-3287-9000 / Fax +82-2-3287-9069 / www.otsuka.co.kr/Customer Call +82-080-558-2036

Samsca®
(tolvaptan)

0-SAM-17-ADPKD-012-01 / May. 2017

INDICATIONS
1. Renal anemia
2.Chernotherapy induced anemia in solid cancer patients

DOSAGE AND ADMINISTRATION
<Hemodialysis patients>
-Initial dose
The usual dose of NESP in adult patients is 20 ㎍, to be administered as a single intravenous injection once weekly.
-Initial dose at the switching from erythropoietin preparations: See Precautions related to Dosage and Administration
-Maintenance dose
When correction of anemia is achieved, the usual dose of NESP in adult patients is 15-60 ㎍ as darbepoetin alfa (genetical recombination), to be administered as a single intravenous injection once weekly. If alleviation of anemia is maintained by once weekly injection, the frequency of administration can be changed to once every two weeks with an initial dose set to be two-fold of the dose in the once weekly injection. In this case, the usual dose in adult patients is 30-120 ㎍ administered as a single intravenous injection once every two weeks. In all cases, the doseshould be adjusted in view of the degree of anemic symptoms and the patient's age, and should not exceed 180 ㎍ as a single injection. The target of anemia correction is around 11 g/dl of hemoglobin level.
<Peritoneal dialysis patients and patients with chronic kidney disease not on dialysis>
-Initial dose
The usual dose of NESP in adult patients is 30㎍ to be administered as a single injection once every two weeks subcutaneously or intravenously.
-Initial dose at the switching from erythropoietin preparations: See Precautions related to Dosage and Administration
-Maintenance dose
When correction of anemia is achieved, the usual dose of NESP in adult patients is 30-120㎍ as darbepoetin alfa (genetical recombination), to be administered as a single injection once every two weeks subcutaneously or intravenously. If alleviation of anemia is maintained by once every two weeks injection, the frequency of administration can be changed to once every four weeks with a initial dose set to be two-fold of the dose in the once every two weeks injection. In this case, the usual dose in adult patients is 60-180 ㎍ administered as a single injection once every four weeks subcutaneously or intravenously. In all cases, the dose should be adjusted in view of the degree of anemic symptoms and the patient's age, and should not exceed 180 ㎍ as a single injection. The target of anemia correction is around 11g/dl of hemoglobin level.

<Precautions related to Dosage and Administration>
1. Initial dose at the switching from an erythropoietin preparation.
When NESP is started in substitution for an erythropoietin preparation, the dose and the frequency of administration should be determined on the basis of the dose of the erythropoietin preparation that has been used. See the table (package insert).

1) Patients who have been treated with an erythropoietin preparation twice weekly or three times weekly Calculate the total dose of the erythropoietin preparation administered during the week before the switching, and then determine the initial dose of NESP according to the table below. The treatment should be started on once weekly basis.
2) Patients who have been treated with an erythropoietin preparation once weekly or once every two weeks Calculate the total dose of the erythropoietin preparation administered during the two weeks before the switching, and then determine the initial dose of NESP according to the table below. The treatment should be started on once every two weeks basis.(See the insert paper,

2. Dose adjustment
If dose adjustment is required (for example, when the appropriate increase in the hemoglobin concentration or the hematocrit levels can not be achieved in correction phase, or when the hemoglobin concentration or the hematocrit level deviates from the target range for successive two weeks in maintenance phase), the dose should be increased or decreased according to the table below. Any dose increase should be performed stage by stage in principle.

PRECAUTIONS
See the package insert.

STORAGE
Store in a lightproof container at 2-8 °C and avoid freezing

PACKAGING
1 syringe, 10 syringes
for NESP 20㎍, 30㎍, 40 ㎍, 60㎍, 120㎍, respectively

MANUFACTURED BY :

Taiyo Pharmaceutical Co., Ltd.
1040-22 Matunoki Takayama-shi Gifu, Japan

Kyowa Hakko Kirin Co., Ltd.
100-1 Hagiwara-machi, Takasaki-shi, Gunma, Japan

IMPORTED BY :

KYOWA KIRIN

Kyowa Hakko Kirin Korea Co., Ltd.
11F, Asia Tower, 430, Nonhyeon-ro, Gangnam-gu, Seoul, 06223, Rep. of Korea
TEL: 02-3471-4321 FAX: 02-3471-4322
Http://www.kyowa-kirin-korea.com

The Right Key
to High Bleeding Risk Patients in HD & CRRT!

HD: hemodialysis, CRRT: continuous renal replacement therapy

FUTHAN is an anticoagulant during extracorporeal blood circulation in patients with bleeding complications or bleeding tendency.[1]

FUTHAN Inj.

- Due to its short half life (5~8 min), its anticoagulant activity is almost limited to extracorporeal circuit.[2,3,4]
- Increase of bleeding risk was not noted in HD patients with bleeding risk.[5,6,7]
- The filter-life is significantly prolonged during CRRT[8,9,10]

Summary of Prescribing Information[1]

Prescribing drug | MFDS Category number: 399

【PRODUCT NAME IN KOREA】• Futhan for Inj. (nafamostat mesilate) • Futhan50 for Inj. (nafamostat mesilate) 【INGREDIENT】• Futhan for Inj. : 1 vial contains 10mg of nafamostat mesilate • Futhan50 for Inj. : 1 vial contains 50mg of nafamostat mesilate 【INDICATION AND USAGE】 1. For improvement of acute symptoms of pancreatitis (acute pancreatitis, acute exacerbation of chronic pancreatitis, acute postoperative pancreatitis, ERCP-induced acute pancreatitis, traumatic pancreatitis) – Futhan for Inj. only 2. Disseminated intravascular coagulation (DIC) 3. To prevent coagulation of blood during extracorporeal blood circulation (ex. hemodialysis, plasmapheresis) in patients with bleeding complications or bleeding tendency. 【DOSAGE AND ADMINISTRATION】 … 3. To prevent coagulation of blood during extracorporeal blood circulation (ex. hemodialysis, plasmapheresis) in patients with bleeding complications or bleeding tendency. For priming, wash and fill the blood route with 20mg of nafamostat mesilate dissolved in 500mL of saline after dissolving in the small amount of 5% glucose solution or water for injection. After beginning of extracorporeal circulation, inject continuously at a rate of 20~50mg/hr as nafamostat mesilate dissolved in 5% glucose solution into anticoagulant injection line. The dosage should be appropriately adjusted according to the patient's symptoms. The average dosage from clinical study is 35mg/hr as nafamostat mesilate. … **Manufactured by** Yuhan corporation, **Distributed by** SK chemicals **Revised:** May 28, 2018.
※ For the details, you are recommended to check on prescribing information. The latest approved label is available on the website following. http://nedrug.mfds.go.kr

References 1. Prescribing information of Futhan for Inj., Futhan50 for Inj. NeDrug. [Cited 2019 MAR 27] Available from: http://nedrug.mfds.go.kr/ **2.** H, Hirasawa. Theoretical consideration and practice of CHDF. Japan;総合医学史;1998. p.25–30. **3.** Ohtake Y et al. Contrib Nephrol. 1991;93:215–7. **4.** Shinoda T. Contrib Nephrol. 2010;166:119–25. **5.** Akizawa T et al. Artificial Organs. 1991;14:209–12. **6.** Kim HC et al. Korean J Nephrol. 2004 Nov;23(6):920–6. **7.** Akizawa T et al. Nephron. 1993;64(3):376–81. **8.** Park II et al. Korean J Nephrol. 2009;28(3):205–10. **9.** Hwang SD et al. Int J Artif Organs. 2013 Mar;36(3):208–16. **10.** Choi JY et al. Medicine (Baltimore). 2015 Dec;94(52):e2392

SK chemicals
Life Science Biz. 310, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, Korea Tel. +82-2-2008-2900 www.skchemicals.com

FTN-HA06-201903-01

Making adherence part of their daily lives

FOSRENOL®
(lanthanum carbonate)

Effective phosphate management, simplified

- **Increased Patient Satisfaction :** Effective control with 3000mg/day [1]
- **Reduce Pill Burden :** One tablet or powder each meal [2]
- **Well Established Safety Profile :** Over 10 years of safety data [3]

Reference 1. Vemuri, et al. *BMC Nephrology* 2011, 12:49 2. Wilson RJ et al. *Adv Ther* (2013) 30:1100–1110 3. Hutchinson AJ et al. *Nephrology* 2016; 21: 987-994

PRESCRIBING INFORMATION. (Before prescribing please consult the full Summary of Product Characteristics (SmPC).) **Presentation:** Chewable tablets containing 500 mg, 750 mg of lanthanum (as lanthanum carbonate hydrate). Oral powder containing 1000 mg of lanthanum (as lanthanum carbonate hydrate). Both the chewable tablets and oral powder contain dextrates, containing glucose. **Uses:** Fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphatemia in chronic renal failure patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 5.5 mg/dL in whom a low phosphate diet alone is insufficient to control serum phosphate levels. **Dosage and Administration:** For oral use. Adults, including older people (> 65 years): Fosrenol should be taken with or immediately after food, with the daily dose divided between meals. The tablets must be chewed completely and not swallowed whole. To aid with chewing the tablets may be crushed. Fosrenol oral powder is intended to be mixed with a small quantity of soft food (e.g. applesauce or other similar food product) and consumed immediately (within 15 minutes). The dose of Fosrenol should be titrated every 2 3 weeks until an acceptable serum phosphate level is reached. Control of serum phosphate level has been demonstrated at doses starting from 750mg per day. The maximum daily dose studied, in a limited number of patients, is 3750mg. Patients who respond to lanthanum therapy usually achieve acceptable serum phosphate levels at doses of 1500 3000mg lanthanum per day. Pediatric population (<18 years): The safety and efficacy of Fosrenol in children and adolescents has not been established; use in children and adolescents is not recommended. Hepatic impairment: The effect of hepatic impairment on Fosrenol pharmacokinetics has not been assessed. Due to its mechanism of action and the lack of liver metabolism, doses in hepatic impairment should not be modified, but patients should be monitored carefully **Adverse Effects:** Very common: (≥1/10): headache, abdominal pain, diarrhea, nausea, vomiting, allergic skin reactions. Common: (≥1/100 to <1/10 patients): constipation, dyspepsia, flatulence, hypocalcaemia. Consult SmPC in relation to less common side effects. **Date of Revision:** March 2018.
For further information, please refer to the latest prescribing information at www.jwpharma.co.kr or http://drug.mfds.go.kr

JW Pharmaceutical

JW Pharmaceutical
2477, Nambusunhwan-ro, Seocho-gu, Seoul, 06725, Korea
Tel: +82-2-840-6777 **Customer Call** +82-1588-2675
www.jw-pharma.co.kr

Takeda

KOR/C-APROM/KOR//0870

Roche

SAVE with MIRCERA®

MIRCERA® saves valuable moments for patients with CKD and healthcare professionals.

* CKD : Chronic kidney disease

References 1. MIRCERA® product information 2. De Cock, et al. Time-and-motion study of C.E.R.A. once monthly. Journal of Medical Economics. 2013;16(5):648-656. 3. Ulrich Saueressaig, et al. Healthcare Resource Utilization for Anemia Management: Current Practice with Erythropoiesis-Stimulating Agents and the Impact of Converting to Once-Montyly C.E.R.A. Blood Purif 2008;26:537. 4. Weinreich T, et al. on behalf of the SESAM study group. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodialysis International 2012;16:11-19.

MIRCERA®
pre-filled syringe
Prescription medicine, classification number:249

30μg/0.3ml, 50μg/0.3ml, 75μg/0.3ml 100μg/0.3ml, 120μg/0.3ml, 150μg/0.3ml, 200μg/0.3ml, 250μg/0.3ml, 360μg/0.3ml (Methoxy Polyethylene glycol-epoetin beta)

Host cell : CHO cell / Expression vector : DN2-3
Excipients: Stabilizers (Sodium sulphate, Poloxamer 188), Sodium dihydrogen phosphate monohydrate, Mannitol (E421), Methionine, Hydrochloric acid, Sodium hydroxide,Solvent: (Water for injections)

Pharmaceutical Form: Solution for injection in pre-filled syringe (injection). The solution is clear and colorless to slightly yellowish. Therapeutic indication: Treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adult patients. Method administration and dosage: MIRCERA should be administered either subcutaneously or intravenously. It can be injected subcutaneously in the abdomen, arm or thigh. Treatment with MIRCERA is normally long-term. However, it can be interrupted at any time, if necessary. It is recommended that haemoglobin is monitored every two weeks until stabilized and periodically thereafter. If one dose of MIRCERA is missed, the missed dose is to be administered as soon as possible and administration of MIRCERA is to be restarted at the prescribed dosing frequency. 1. Patients currently not treated with an erythropoiesis stimulating agent (ESA): In order to increase haemoglobin levels to greater than 10 g/dl (6.21 mmol/l), the recommended starting dose in patients on dialysis and patients not on dialysis is 0.6μg/kg on every 2 weeks administration (SC or IV). If patient is not on dialysis, starting dose can be 1.2 μg/kg body weight, administered once every month as a single subcutaneous injection. The dose may be increased by approximately 25% of the previous dose if the rate of rise in haemoglobin is less than 1.0 g/dl (0.621 mmol/l) over a month. Further increases of approximately 25% may be made at monthly intervals until the individual target haemoglobin level is obtained. If the rate of rise in haemoglobin is greater than 2 g/dl (1.24 mmol/l) in one month or if the haemoglobin level is increasing and approaching 12 g/dl (7.45 mmol/l), the dose is to be reduced by approximately 25%. If the haemoglobin level continues to increase, therapy should be interrupted until the haemoglobin level begins to decrease, at which point therapy should be reduce approximately 25% from the previously administered dose. After dose interruption a haemoglobin decrease of approximately 0.35 g/dl (0.22 mmol/l) per week is expected. Dose adjustments should not be made more frequently than once a month. Patients treated once every two weeks whose haemoglobin concentration is above 10 g/dl (6.21 mmol/l) may receive MIRCERA administered once-monthly using the dose equal to twice the previous once-every-two-week dose. 2. Patients currently treated with an ESA: Patients currently treated with an ESA can be switched to MIRCERA administered once a month as a single intravenous or subcutaneous injection. The starting dose of MIRCERA is based on the calculated previous weekly dose of darbepoetin alfa or epoetin at the time of substitution as described in Table 1. The first injection should start at the next scheduled dose of the previously administered darbepoetin alfa or epoetin.

Table 1. MIRCERA starting doses

Previous weekly darbepoetin alfa intravenous or subcutaneous dose (microgram/week)	Previous weekly epoetin intravenous or subcutaneous dose (IU/week)	Monthly MIRCERA intravenous or subcutaneous dose (microgram/once monthly)
< 40	< 8000	120
40 – 80	8000 – 16000	200
> 80	> 16000	360

If a dose adjustment is required to maintain the target haemoglobin concentration above 10 g/dl (6.21 mmol/l), the monthly dose may be increased by approximately 25%.If the rate of rise in haemoglobin is greater than 2 g/dl (1.24 mmol/l) over a month or if the haemoglobin level is increasing and approaching 12 g/dl (7.45 mmol/l), the dose is to be reduced by approximately 25%. If the haemoglobin level continues to increase, therapy should be interrupted until the haemoglobin level begins to decrease, at which point therapy should be reduce approximately 25% from the previously administered dose. After dose interruption a haemoglobin decrease of approximately 0.35 g/dl (0.22 mmol/l) per week is expected. Dose adjustments should not be made more frequently than once a month. Since the treatment experience is limited in patients on peritoneal dialysis, regular haemoglobin monitoring and strict adherence to dose adjustment guidance are recommended in these patients. Precautions for use: Special warnings 1. It should be injected the dose keeps maintaining a certain dose for minimum haemoglobin concentration without RBC transfusion. 2. In patients with chronic kidney disease, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended. In clinical trials, an increased risk of death, serious cardiovascular events including thrombosis or cerebrovascular events including stroke was observed when ESAs were administered to target haemoglobin of greater than 12 g/dl (7.5 mmol/l). 3. In patients with advanced head and neck cancer with radiotherapy, metastatic breast cancer with chemotherapy and progressive cancer without chemotherapy and radiotherapy, ESAs were administered to target a haemoglobin of greater than 12 g/dl shorten the time of tumor progression and increase the risk of death. 4. Patients receiving ESAs pre-operatively for reduction of allogeneic red blood cell transfusions: A higher incidence of deep venous thrombosis was documented. Contraindications: 1. Hypersensitivity to the active substance or to any of the excipients. 2. Uncontrolled hypertension. Precautions for following types of patients who are with: 1. Severe liver disease. 2. Haemoglobinopathies. 3. Seizures. 4. Recent history of bleeding or bleeding requiring transfusions or with platelet levels greater than 500 x 109/l.

MIRCERA-2015-10-22-1.0

MC2017113O-001

Roche Korea. 17th Floor, GT Tower(East), 411, Seocho-daero, Seocho-gu, Seoul
1) For more detailed product information and/or to report an adverse event, please contact Roche Korea (02-3451-3600)
2) For the latest product information, please visit Roche Korea website at www.roche.co.kr.

MIRCERA®
methoxy polyethylene glycol-epoetin beta

BORYUNG

TORECA

TOTAL RENAL CARE

One-Chart Care

통합적 파이프라인을 구축하여
원스탑 서비스를 제공하겠습니다.

Lifetime Care

환자의 건강을 항상 먼저 생각하고,
평생을 케어하겠습니다.

Care Companion

치료전문가가 최적의
솔루션 조합을 찾는 데 함께
하겠습니다.

Sustainable Care

지속적인 제품 개발과 서비스
향상을 위해 노력하겠습니다.

보령제약 신장사업본부는 **TOTAL RENAL CARE**를 제공합니다.

| 보령제약 | 서울특별시 종로구 창경궁로 136 보령빌딩 소비자상담실 Tel 080.708.8088 Fax 02.741.5291 www.boryung.co.kr

'투석 시작' 시기를 지연시키는 신부전 진행억제제[1]

씨제이 크레메진® 세립
KREMEZIN

투석 시작 시기 지연[1]

요독증 개선 및 완화[2]

QOL 향상[3]

사회 · 경제적 이득효과[3]

kolmar 씨제이헬스케어

서울특별시 중구 을지로 100 파인에비뉴 A동 6-8층 http://www.cjp.co.kr | Tel. 080-700-8802

1005 KRM IMA002.02

제품정보 – 【성분 함량】 kremezin 2g 【효능 효과】 만성신부전증(진행성)에 대한 요독증 증상의 개선 및 투석도입의 지연 【용법 용량】 성인 1일 3회, 1회 2그람(1포) 복용 【사용상의 주의사항】 및 기타 자세한 내용은 제품설명서를 참조하시기 바랍니다.

References – 1. The Journal of International Medical Research 2009;37(1):1-9 2. Clinical Evaluation 1987;15(3):527-564 3. Nephrology 2008;13:419-427

Contents

KSN 2019
SEOUL, KOREA MAY 23 - 26

Overview

Title	The 39th Annual Meeting of the Korean Society of Nephrology (KSN 2019)
Date	May 23 (Thu) – 26 (Sun), 2019
Place	Seoul Dragon City, Seoul, Korea
Hosted by	The Korean Society of Nephrology, The Research Institute of Kidney Disease
Official Language	English, Korean
Program	Opening Ceremony, Plenary Sessions, Invited Lecture Sessions, Oral & Poster Sessions, Exhibition, Welcome Reception
Contact	**The Korean Society of Nephrology** #1401, 42 Seocho-daero 78-gil, Seocho, Seoul, 06626, Korea **Tel.** +82-2-3486-8736 **Fax.** +82-2-3486-8737 **Email.** ksn@ksn.or.kr **KSN 2019 Secretariat** InSession International Convention Services, Inc. 4Fl. 10, Yeoksam-ro 7-gil, Gangnam-Gu, Seoul, 06244, Korea **Tel.** +82-2-538-4603 **Fax.** +82-2-521-8683 **E-mail.** office@ksnmeeting.kr

The Korean Society of Nephrology Organization

Organizing Committee

President	Yon Su Kim, M.D.	**Congress President**	Nam Ho Kim, M.D.
Congress Vice-President	Mee Kyung Namgoong, M.D.	**Auditor**	Sun Ae Yoon, M.D.
Secretary General	Dong Ki Kim, M.D.	**Vice-Secretary General**	Jung Pyo Lee, M.D. Hye Eun Yoon, M.D. Jang-Hee Cho, M.D. Hyung Jong Kim, M.D.
Editor-in-Chief, Kidney Research and Clinical Practice	Gheun-Ho Kim, M.D.	**Chair, the Scientific Programs**	Bum Soon Choi, M.D.
Chair, the External Affairs and Cooperation	Hyeong Cheon Park, M.D. Sang Kyung Jo, M.D.	**Chair, the Publication**	Eun Young Lee, M.D.
Chair, the Training and Education	Chan-Duck Kim, M.D.	**Chair, the ESRD Registry**	Young-Soo Kim, M.D. Dong-Ryeol Ryu, M.D.
Chair, the Insurance and Legal Affairs	Byoung Geun Han, M.D. Seong Nam Kim, M.D.	**Treasurer**	Seok Joon Shin, M.D.
Chair, the Ethical Issues	Sang Wook Kim, M.D. Sung Joon Shin, M.D.	**Chair, the Public Relation**	Jung Eun Lee, M.D.
Chair, the Dialysis Quality Assurance	Young-Ki Lee, M.D. Myeong Seong Kim, M.D.	**Chair, the Planning**	Seung Hyeok Han, M.D.
Chair, at Large	Dong Won Lee, M.D. Soon Kil Kwon, M.D. Sejoong Kim, M.D. Beom Jin Lim, M.D.		

The Korean Society of Nephrology Organization

Advisory Board

Acute Kidney Injury

Chair Sang Kyung Jo, M.D.

Member Dong-Jin Oh, M.D.
Hyo-Wook Gil, M.D.
Myung-Gyu Kim, M.D.
Hyeong Cheon Park, M.D.
Hye Ryoun Jang, M.D.
Hoon Young Choi, M.D.

Diabetes and Obesity

Chair Cheol Whee Park, M.D.

Member Young Sun Kang, M.D.
Hyunjin Noh, M.D.
Jung Tak Park, M.D.
Hye Eun Yoon, M.D.
Eun Young Lee, M.D.
Jung Pyo Lee, M.D.
Hunjoo Ha, M.D.

Dialysis (PD)

Chair Yong-Lim Kim, M.D.

Member Sun-Hee Park, M.D.
Dong-Ryeol Ryu, M.D.
JongHa Park, M.D.
Dae Eun Choi, M.D.

Glomerular and Tubulointerstitial Disorders (CKD)

Chair Ho Jun Chin, M.D.

Member Shin Young Ahn, M.D.
Dong-Ryeol Ryu, M.D.
Sun-Hee Park, M.D.
Joon Ho Song, M.D.
Se Won Oh, M.D.
Sung Woo Lee, M.D.
Hajeong Lee, M.D.
Bum Soon Choi, M.D.
Seung Hyeok Han, M.D.

Inherited Kidney Disease (Pediatric Nephrology)

Chair Kee Hwan Yoo, M.D.

Member Hee Gyung Kang, M.D.
Min Hyun Cho, M.D.
Hee Yeon Cho, M.D.
Il Soo Ha, M.D.

Dialysis (HD)

Chair Yong-Soo Kim, M.D.

Member Sung Gyun Kim, M.D.
Sejoong Kim, M.D.
Young Ok Kim, M.D.
Ju-Young Moon, M.D.
Sug Kyun Shin, M.D.
Young-il Jo, M.D.

Fluid, Electrolyte and Acid-Base

Chair Gheun-Ho Kim, M.D.

Member Eun Hui Bae, M.D.
Won Kim, M.D.
Kyung Hwan Jeong, M.D.
Sang-Youb Han, M.D.

Hypertension and Vascular Biology

Chair Soo Wan Kim, M.D.

Member Eun Hui Bae, M.D.
Kyung Pyo Kang, M.D.
Gang Jee Ko, M.D.
JongHa Park, M.D.
Wonsuk An, M.D.
Jung Pyo Lee, M.D.
Harin Rhee, M.D.
Seungyeup Han, M.D.

Transplantation

Chair Chul Woo Yang, M.D.

Member Beom Seok Kim, M.D.
Hyosang Kim, M.D.

Scientific Committee

Chair Bum Soon Choi, M.D.

Member
Jung Tak Park, M.D.
Byung Seung Kang, M.D.
Yong Kyun Kim, M.D.
Kwon Moo Park, M.D.
Sang Heon Song, M.D.
Tae Ik Chang, M.D.
Eunsil Koh, M.D.
Young Sun Kang, M.D.
Jwa-Kyung Kim, M.D.
Sun-Hee Park, M.D.
Jiwon Lee, M.D.
Kyung Hwan Jeong, M.D.
Kyung Pyo Kang, M.D.
Ghee Young Kwon, M.D.
Hyosang Kim, M.D.
Eun Hui Bae, M.D.
Hajeong Lee, M.D.
Dae Eun Choi, M.D.

Welcome Message

Dear colleagues,

It is our great pleasure to invite you to the 39th Annual Meeting of the Korean Society of Nephrology (KSN 2019) which will be held at Seoul Dragon City, Seoul, Korea from May 23 to 26, 2019.

One of the major missions of KSN is to add depth to the international exchanges that take place at KSN meetings and to provide various educational opportunities for the society members. Since its foundation in 1980, KSN has organized national scientific meetings and expanded it as an international meeting in 2016, making KSN 2019 its 4th international meeting.

In 2018, almost 1,600 delegates attended the KSN 2018, and 39 overseas experts from 22 countries were invited to give engaging lecture and provocative discussion. Under the theme of ***"Peaceful Kidneys, Save Lives,"*** KSN 2019 is preparing an international congress with sessions on hot topics such as the ***Artificial Intelligence in Medical Field*** and the most recent updates in various fields of nephrology. Joint symposia with related societies will be actively held including the KSN-APSN Joint CME course, KSN-KDIGO joint symposium, and KSN-TSN-JSDT joint symposium. We firmly believe that KSN 2019 will be a more flourished international meeting in both quality and quantity.

We cordially encourage you to join us at KSN 2019 and enjoy this opportunity by sharing your valuable expertise and experiences with key opinion leaders in the global nephrology community to deepen your knowledge and broaden your global network.

We will look forward to seeing you at KSN 2019 in Seoul.

Sincerely yours,

Yon Su Kim, M.D.
President
Korean Society of Nephrology

Nam Ho Kim, M.D.
Congress President
Korean Society of Nephrology

Floor Plan



3F

- Room 1
- Room 2
- Exhibition Hall
- Preview Room
- Small Meeting Room 1-3
- Secretariat



4F

- Room 6
- Internet Lounge
- Faculty Lounge



5F

- Room 3
- Room 4
- Exhibition Hall
- Room 5
- Registration Desk

Facility Operating Hours

Facility	Location	Operating Hours			
		May 23 (Thu)	May 24 (Fri)	May 25 (Sat)	May 26 (Sun)
Registration Desk	Lobby, 5F	12:00-16:30	08:00-16:00	08:00-16:00	08:00-11:00
Preview Room	VIP room, 3F	11:00-18:20	07:00-19:00	07:00-19:00	07:00-13:00
Faculty Lounge	Baekje 6-7, 4F	12:00-18:30	08:00-18:30	08:00-18:30	08:00-13:30
Internet Lounge	Lobby, 4F	12:00-18:30	08:00-18:30	08:00-18:30	08:00-13:30
Exhibition	Exhibition Halls 3F & 5F	13:00-18:20	09:00-18:00	08:30-18:00	Closed
	Lobby, 3F & 5F	13:00-18:20	09:00-18:00	08:30-18:00	08:00-13:00
Coffee Break	Lobby, 5F	12:00-13:00 17:00-17:20	08:00-09:00	08:00-08:30	08:00-08:30 10:30-11:00
Coffee Station (in Exhibition Hall)	Exhibition Hall, 3F	Closed	09:00-18:00	08:30-18:00	Closed
	Exhibition Hall, 5F	Closed	09:00-18:00	08:30-18:00	Closed

Program at a glance

Korean Session | English Session | Simultaneous interpretation will be provided (English ↔ Korean)

May 23. Thursday

Time	Room 1 Hanra A (3F)	Room 2 Hanra B (3F)	Room 3 Baekdu A (5F)	Room 4 Baekdu B (5F)	Room 5 Goguryeo (5F)	Room 6 Baekje (4F)	Poster/Exhibition Hanra(3F) /Baekdu(5F)
12:00-13:00	Registration						
13:00-15:00	Glomerular & Tubulointerstitial Disease 1	End Stage Renal Disease, Dialysis (Nephrology Board Review Course 1)	Kidney Academy	Oral Communications: Dialysis 1	The Research and Development of New Drugs		Exhibition
15:00-17:00	Acute Kidney Injury 1	End Stage Renal Disease, Dialysis (Nephrology Board Review Course 2)	Oral Communications: Transplantation 1	Oral Communications: Diabetes and Obesity 1	KSN research fund project/Overseas research studies topic presentation		
17:00-17:20	Break						
17:20-17:30	Opening Ceremony						
17:30-18:20	Plenary Lecture 1 *Benjamin S. Freedman (USA)*						
19:00-21:00			Welcome Reception				

May 24. Friday

Time	Room 1 Hanra A (3F, Interpretation)	Room 2 Hanra B (3F, Interpretation)	Room 3 Baekdu A (5F)	Room 4 Baekdu B (5F)	Room 5 Goguryeo (5F)	Room 6 Baekje (4F)	Poster/Exhibition Hanra(3F) /Baekdu(5F)
08:00-09:00	Registration						
09:00-11:00	Acute Kidney Injury 2	Kidney Transplantation 1	Urinary Acidification and Renal Tubular Acidosis	Oral Communications: Glomerular and Tubulointerstitial Disorders (CKD) 1	Oral Communications: Diabetes and Obesity 2 / Hypertension and Vascular Biology		Poster / Exhibition
11:00-11:30	Poster Visit & Break						
11:30-12:30	Luncheon Symposium SK Chemicals / YUHAN / JW Pharmaceutical / HANDOK						
12:30-13:00	Poster Visit & Break						
13:00-13:50	Plenary Lecture 2 *Raymond C. Harris (USA)*						
13:50-14:00	Poster Visit & Break						
14:00-15:00	Basic Research	Hemodialysis 1	APSN-KSN Joint CME Course 1	Oral Communications: Acute Kidney Injury 1	Future Medicine/ Hot Issue	Meet the Expert (Small Meeting Room 1, 2)	
15:00-16:00							
16:00-18:00	Pediatric Nephrology	Diabetes	APSN-KSN Joint CME Course 2	Oral Communications: Non-dialysis CKD 1	Becoming a New Basic Researcher		
18:00-18:10	Break						
18:10-19:10	Dinner Symposium Takeda Pharmaceuticals Korea Co., Ltd.						

May 25. Saturday

Time	Room 1 Hanra A (3F, Interpretation)	Room 2 Hanra B (3F, Interpretation)	Room 3 Baekdu A (5F)	Room 4 Baekdu B (5F)	Room 5 Goguryeo (5F)	Room 6 Baekje (4F)	Poster/Exhibition Hanra(3F) /Baekdu(5F)
07:00-08:00			KSN Board of Regent				
08:00-08:30	Registration			Registration			
08:30-09:00	Glomerular & Tubulointerstitial Disease 2	Interventional Nephrology (Hemodialysis 2)	CPC	Oral Communications: Acute Kidney Injury 2	KSN ESRD Registry Report		Poster / Exhibition
09:00-10:00						KSN Cooperative Study	
10:00-11:00	Risk Assessment and Decision Making in Transplantation (Kidney Transplantation 2)	Peritoneal Dialysis	Pathology	Oral Communications: Dialysis 2	Diabetic Kidney Disease (KSN-TSN-JSDT Joint Symposium)	Oral Communications: Inherited Kidney Disease / Fluid, Electrolyte and Acide-Base / Non-dialysis CKD 2	
11:00-12:00							
12:00-13:00	Luncheon Symposium Baxter / Fresenius Medical Care Korea / Korea Otsuka Pharmaceutical Co., Ltd. / Kyowa Hakko Kirin Korea Co., Ltd.						
13:00-14:00			General Assembly				
	Poster Visit & Break						
14:00-14:50	Plenary Lecture 3 *Anna Greka (USA)*						
14:50-15:00	Poster Visit & Break						
15:00-16:00	KSN-ISN Joint Symposium (Inter-Korea Medical Cooperation: Nephrology Perspective)	KDIGO-KSN Joint Symposium	Chronic Kidney Disease and Nutrition (KSN-KSCN Joint Symposium -Korean Society of Clinical Nutrition)	Oral Communications: Transplantation 2	Dialysis Committee	"Act on Decisions on Life-Sustaining Treatment" and Hemodialysis	
16:00-16:30							
16:30-17:00			Hypertension & Vascular Biology	Oral Communications: Glomerular and Tubulointerstitial Disorders (CKD) 2	KSN-KCCP Joint symposium (Korean College of Clinical Pharmacy)		
17:00-18:00	Shared Decision-Making for Renal Replacement Treatments (Ethics Education)						
18:00-18:30							

May 26. Sunday

Time	Room 1 Hanra A (3F)	Room 2 Hanra B (3F)	Room 3 Baekdu A (5F)	Room 4 Baekdu B (5F)	Room 5 Goguryeo (5F)	Room 6 Baekje (4F)	Poster/Exhibition Hanra(3F) /Baekdu(5F)
08:00-08:30	Registration						
08:30-10:30	Dialysis Nurse Course 1	Blood Pressure and the Kidney (KSN-KSH Joint symposium - Korean Society of Hypertension)	Hands-on session	New policy in CKD-MBD management (Dialysis Specialist Physician Course 1)			
10:30-11:00	Break						
11:00-13:00	Dialysis Nurse Course 2	KSN-KES Joint symposium (Korean Endocrine Society)	Hands-on session	Common problem in hemodialysis patients (Dialysis Specialist Physician Course 2)			
13:00-13:30							

Detailed Program

May 23 (Thu)

13:00-15:00	**Glomerular & Tubulointerstitial Disease 1**	GN 01	KOR	Room 1
Chair(s)	**Seok Joon Shin** *The Catholic University of Korea, Korea* **Jung Hwan Park** *Konkuk University, Korea*			
GN 01-01	**Criteria of surrogate markers to estimate CKD outcomes**		**Mi-yeon Yu** *Hanyang University, Korea*	
GN 01-02	**Blood pressure and CKD progression**		**Seung Hyeok Han** *Yonsei University, Korea*	
GN 01-03	**Lowering uric acid level to prevent CKD progression - Pros**		**Sang-Youb Han** *Inje University, Korea*	
GN 01-04	**Lowering uric acid level to prevent CKD progression - Cons**		**Hoon Young Choi** *Yonsei University, Korea*	

13:00-15:00	**Nephrology Board Review Course 1 - End Stage Renal Disease, Dialysis**	BRC 01	KOR	Room 2
Chair(s)	**Seungyeup Han** *Keimyung University, Korea*			
BRC 01-01	**Dialysis adequacy (HD/PD adequacy issues)**		**Do Hyoung Kim** *Hallym University, Korea*	
BRC 01-02	**Management of secondary hyperparathyroidism in dialysis patients**		**Gang Jee Ko** *Korea University, Korea*	
BRC 01-03	**Incremental, hybrid, and extended dialysis**		**Kook-Hwan Oh** *Seoul National University, Korea*	
BRC 01-04	**Individualization of dialysate in hemodialysis**		**Hyosang Kim** *University of Ulsan, Korea*	

15:00-17:00	**Nephrology Board Review Course 2 - End Stage Renal Disease, Dialysis**	BRC 02	KOR	Room 2
Chair(s)	**Sang Heon Song** *Pusan National University, Korea*			
BRC 02-01	**Clinical implications and prescriptions of on-line HDF**		**Chang Seong Kim** *Chonnam National University, Korea*	
BRC 02-02	**Prescription of automated peritoneal dialysis**		**Jang-Hee Cho** *Kyungpook National University, Korea*	
BRC 02-03	**Evaluation and management of failing AVF**		**Ki Ryang Na** *Chungnam National University Hospital, Korea*	
BRC 02-04	**Non-infectious peritoneal dialysis complications**		**Sun-Hee Park** *Kyungpook National University, Korea*	

13:00-15:00	**Kidney Academy**	KA	KOR	Room 3
Chair(s)	**Dong Ki Kim** *Seoul National University, Korea*			
KA-01	**Management of hyperphosphatemia in CKD patients**		**Chang Seong Kim** *Chonnam National University, Korea*	
KA-02	**Treatment of anemia in CKD patients**		**Il Young Kim** *Pusan National University, Korea*	
KA-03	**Selection of renal replacement therapy**		**Dae Eun Choi** *Chungnam National University, Korea*	
KA-04	**Healthcare insurance policy for dialysis patients**		**Hyung-Jong Kim** *CHA University, Korea*	

13:00-15:00	**Oral Communications 1 (Dialysis 1)**	OR 01	ENG	Room 4
Chair(s)	**Jun Young Do** *Yeungnam University, Korea* **Sun Ae Yoon** *The Catholic University of Korea, Korea*			
	OR 01 DL-01~OR 01 DL-10			

13:00-15:00	**The Research and Development of New Drugs**	ND	ENG	Room 5
Chair(s)	**Chun Soo Lim** *Seoul National University, Korea* **Cheol Whee Park** *The Catholic University of Korea, Korea*			
ND-01	**Microbiome for metabolic and kidney diseases**		**GwangPyo Ko** *Seoul National University, Korea*	
ND-02	**VM202, a DNA-based potential disease-modifying treatment for painful diabetic neuropathy and foot ulcer**		**Seung Shin Yu** *ViroMed, Korea*	
ND-03	**Bardoxolone methyl: An anti-oxidative, anti-inflammatory agent for kidney diseases**		**Kengo Yamawaki** *Kyowa Hakko Kirin Co., Ltd., Japan*	
ND-04	**The novel oral calcimimetic, evocalcet**		**Yuichiro Kondo** *Kyowa Hakko Kirin Co., Ltd., Japan*	

15:00-17:00	**Acute Kidney Injury 1**	AKI 01	KOR	Room 1
Chair(s)	**Won Yong Cho** *Korea University, Korea* **Seong Kwon Ma** *Chonnam National University, Korea*			
AKI 01-01	**Acute kidney injury in the geriatric population**		**Eun Young Seong** *Pusan National University, Korea*	
AKI 01-02	**Automated acute kidney injury alerts**		**Sejoong Kim** *Seoul National University, Korea*	
AKI 01-03	**Interesting cases of AKI 1 (Interactive)**		**Myung-Gyu Kim** *Korea University, Korea*	
AKI 01-04	**Interesting cases of AKI 2 (Interactive)**		**Jang-Hee Cho** *Kyungpook National University, Korea*	

Detailed Program

15:00-17:00	**Oral Communications 2 (Transplantation 1)**	OR 02	ENG	Room 3
Chair(s)	**Dong-Wan Chae** *Seoul National University, Korea* **Beom Seok Kim** *Yonsei University, Korea*			
	OR 02 KT-01~OR 02 KT-10			

15:00-17:00	**Oral Communications 3 (Diabetes and Obesity 1)**	OR 03	ENG	Room 4
Chair(s)	**Eun Young Lee** *Soonchunhyang University, Korea* **Hyunjin Noh** *Soonchunhyang University, Korea*			
	OR 03 DO-01~OR 03 DO-10			

15:00-17:00	**KSN Research Fund Project/Overseas Research Studies Topic Presentation**	RS/OTP	KOR	Room 5
Chair(s)	**Ho Jun Chin** *Seoul National University, Korea* **Sang-Ho Lee** *Kyung Hee Univeresity, Korea*			

RS/OTP-01	Role of myeloid TGF-β receptor in renal fibrosis after acute kidney injury	**Sungjin Chung** *The Catholic University of Korea, Korea*
RS/OTP-02	Sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, does not ameliorate non-diabetic renal injury	**Young Sun Kang** *Korea University, Korea*
RS/OTP-03	Effects of Belimumab, an anti-B lymphocyte stimulator (anti-BlyS) antibody, on the HLA-A2.1 Sensitized mice model	**Ji-Won Min** *The Catholic University of Korea, Korea*
RS/OTP-04	Effect of environment and air pollution on the prognosis of patients with chronic kidney disease	**Jung Pyo Lee** *Seoul National University, Korea*
RS/OTP-05	Application of 3D kidney-on-a-chip for contrast-induced nephropathy	**Kipyo Kim** *Seoul National University, Korea*
RS/OTP-06	Elevated sduble ST2 levels but not galectin - 3 is associated with renal progression and adverse clinical outcomes in non-dialysis patients with chronic kidney disease	**Ae Jin Kim** *Gachon University, Korea*
RS/OTP-07	Selective decontamination of digestive tract attenuates kidney ischemia/reperfusion injury and distant organ damage via immune modulatory effect	**Jihyun Yang** *Korea University, Korea*
RS/OTP-08	Loss of renal peritubular capillaries in hypertensive patients is detectable by urinary endothelial microparticle levels	**In O Sun** *Presbyterian Medical Center, Korea*
RS/OTP-09	Melanocortin system in obesity and kidney disease	**Won Min Hwang** *Konyang University, Korea*

17:20-17:30	**Opening Ceremony**	ENG	Room 1&2

17:30-18:20	**Plenary Lecture 1**	PL 01	ENG	Room 1&2
Chair(s)	**Chul Woo Yang** *The Catholic University of Korea, Korea* **Seong Eun Kim** *Dong-A University, Korea*			
PL 01-01	**Human kidney organoids: Re-creating development and disease**	**Benjamin S. Freedman** *University of Washington, USA*		

May 24 (Fri)

09:00-11:00	**Acute Kidney Injury 2**	AKI 02	ENG ↔ KOR	Room 1
Chair(s)	**Mitchell H. Rosner** *University of Virginia, USA* **Hyeong Cheon Park** *Yonsei University, Korea*			
AKI 02-01	**The Role of macrophages in acute kidney injury**	**Raymond C. Harris** *Vanderbilt University, USA*		
AKI 02-02	**Acute kidney injury in the patient with cancer**	**Mitchell H. Rosner** *University of Virginia, USA*		
AKI 02-03	**The role of SIRT2 in acute kidney injury**	**Won Kim** *Chonbuk National University, Korea*		
AKI 02-04	**Long-term health outcomes of acute kidney injury**	**Jung Nam An** *SMG-SNU Boramae Medical Center, Korea*		

09:00-11:00	**Kidney Transplantation 1** **-Kidney Transplantation Quiz and Questionnaire**	KT 01	ENG ↔ KOR	Room 2
Chair(s)	**Sung Kwang Park** *Chonbuk National University, Korea* **Joong Kyung Kim** *Bong Seng Memorial Hospital, Korea*			
KT 01-01	**Thrombocytopenia after kidney transplantation - Differential diagnosis and evaluation of TMA in KT recipient**	**Tae Hyun Ban** *The Catholic University of Korea, Korea*		
Panel	**Beom Seok Kim** *Yonsei University, Korea* **Chan-Duck Kim** *Kyungpook National University, Korea* **Cheng-Hsu Chen** *Taichung Veterans General Hospital, Taiwan*			
KT 01-02	**Creeping creatinine in KT recipient - Differential diagnosis and management of gradual graft dysfunction**	**Hajeong Lee** *Seoul National University, Korea*		
Panel	**Sang-Ho Lee** *Kyung Hee Univeresity, Korea* **Myung-Gyu Kim** *Korea University, Korea* **Kearkiat Praditpornsilpa** *Chulalongkorn University, Thailand*			

Detailed Program

09:00-11:00	**Urinary Acidification and Renal Tubular Acidosis**	FL	ENG	Room 3
Chair(s)	**Daniel Batlle** *Northwestern University, USA* **Hae Il Cheong** *Seoul National University, Korea*			
FL-01	**Functional anatomy for urinary acidification**			**Tae-Hwan Kwon** *Kyungpook National University, Korea*
FL-02	**Clinical diagnosis of hypokalemic RTA**			**Daniel Batlle** *Northwestern University, USA*
FL-03	**Molecular diagnosis of hypokalemic distal RTA**			**Hae Il Cheong** *Seoul National University, Korea*
FL-04	**Molecular pathogenesis of hyperkalemic distal RTA**			**Min-Hua Tseng** *Chang Gung Memeroal Hospital, Taiwan*

09:00-11:00	**Oral Communications 4 (Glomerular and Tubu lointerstitial Disorders (CKD) 1)**	OR 04	ENG	Room 4
Chair(s)	**Dong-Ryeol Ryu** *Ewha Womans University, Korea* **Sang-Youb Han** *Inje University, Korea*			
	OR 04 GN-01~OR 04 GN-10			

09:00-11:00	**Oral Communications 5 (Diabetes and Obesity 2 / Hypertension and Vascular Biology)**	OR 05	ENG	Room 5
Chair(s)	**JongUn Lee** *Chonnam National University, Korea* **Hunjoo Ha** *Ewha Womans University, Korea*			
	OR 05 DO-01~OR 05 DO-03, OR 05 HV-01~OR 05 HV-07			

11:30-12:30	**Luncheon Symposium 1**	LS 01	KOR	Room 1
	Sponsored by **SK Chemicals**			
Chair(s)	**Kang Wook Lee** *Chungnam National University, Korea*			
LS 01-01	**Zinc deficiency in CKD**			**Bum Soon Choi** *The Catholic University of Korea, Korea*

11:30-12:30	**Luncheon Symposium 2**	LS 02	KOR	Room 2
	Sponsored by **YUHAN**			
Chair(s)	**Cheol Whee Park** *The Catholic University of Korea, Korea*			
LS 02-01	**Linagliptin: the simple choice in DPP-4 inhibition with CARMELINA**			**Jung Tak Park** *Yonsei University, Korea*

11:30-12:30	**Luncheon Symposium 3**	LS 03	KOR	Room 3
	Sponsored by **JW Pharmaceutical**			
Chair(s)	**Young Joo Kwon** *Korea University, Korea*			
LS 03-01	**Experience and long-term safety data of Lanthanum carbonate and Low-phosphrus diet in CKD patients**			**Young-Ki Lee** *Hallym University, Korea*

11:30-12:30	**Luncheon Symposium 4**	LS 04	ENG	Room 4
	Sponsored by **HANDOK**			
Chair(s)	**Sang Kyung Jo** *Korea University, Korea*			
LS 04-01	**Practical approach to the diagnosis and treatment of aHUS. Patient cases are the best teachers.**			**Jan Menne** *Hannover Medical School, Germany*
LS 04-02	**A Korean case of aHUS treated with eculizumab** KOR			**Jung Eun Lee** *Sungkyunkwan University, Korea*

13:00-13:50	**Plenary Lecture 2**	PL 02	ENG ↔ KOR	Room 1&2
Chair(s)	**Yong-Lim Kim** *Kyungpook National University, Korea* **Yon Su Kim** *Seoul National University, Korea*			
PL 02-01	**The role of the EGF receptor family in kidney injury**			**Raymond C. Harris** *Vanderbilt University, USA*

14:00-16:00	**Basic Research**	BR	ENG ↔ KOR	Room 1
Chair(s)	**Joshua H. Lipschutz** *Medical University of South Carolina and Ralph H Johnson Veterans Affairs Medical Center, USA* **Kwon Moo Park** *Kyungpook National University, Korea*			
BR-01	**The role of the exocyst in renal ciliogenesis, cystogenesis, and tubulogenesis**			**Joshua H. Lipschutz** *Medical University of South Carolina and Ralph H Johnson Veterans Affairs Medical Center, USA*
BR-02	**Applications of kidney organoids derived from hPSCs**			**Yong Kyun Kim** *The Catholic University of Korea, Korea*
BR-03	**Molecular mechanisms of ischemic AKI and potential therapies**			**Thomas Lee** *Columbia University, USA*
BR-04	**Potential therapeutic target for diabetic nephropathy**			**Hee-Sook Jun** *Gachon University, Korea*

Detailed Program

14:00-16:00 Hemodialysis 1 — HD 01 — ENG ↔ KOR — Room 2

Chair(s): **Chun Soo Lim** *Seoul National University, Korea*; **Takashi Shigematsu** *Wakayama Medical University, Japan*

HD 01-01	Optimal management for anemia of CKD patients and novel ESAs	**Muh Geot Wong** *The George Institute for Global Health, Australia*
HD 01-02	Effect of dialysate acidification with citrate in hemodialysis patients	**Kyung Hwan Jeong** *Kyung Hee University, Korea*
HD 01-03	Treat or Not osteoporosis in advanced CKD	**Hayne Park** *Hallym University, Korea*
HD 01-04	Clinical update on dialyzer membranes	**Bernd Krause** *Baxter International, Germany*

14:00-16:00 APSN-KSN Joint CME Course 1 — CME 01 — ENG — Room 3

Chair(s): **Kwon Wook Joo** *Seoul National University, Korea*; **Sang Kyung Jo** *Korea University, Korea*

CME 01-01	Oxidative stress and hypoxia as novel therapeutic targets in kidney disease	**Masaomi Nangaku** *The University of Tokyo, Japan*
CME 01-02	Peritoneal dialysis in diabetics	**Yong-Lim Kim** *Kyungpook National University, Korea*
CME 01-03	Current concepts of CKD-MBD	**Kuo-Cheng Lu** *Fu Jen Catholic University, Taiwan*
CME 01-04	Management of renal complications encountered in cancer care	**Jae Wook Lee** *National Cancer Center, Korea*

14:00-16:00 Oral Communications 6 (Acute Kidney Injury 1) — OR 06 — ENG — Room 4

Chair(s): **Hoon Young Choi** *Yonsei University, Korea*; **Jong Woo Yoon** *Hallym University, Korea*

OR 06 AKI-01~OR 06 AKI-10

14:00-16:00 Future Medicine/Hot Issue — FH — KOR — Room 5

Chair(s): **Yon Su Kim** *Seoul National University, Korea*; **Bum Soon Choi** *The Catholic University of Korea, Korea*

FH-01	Digital healthcare, the future of medicine	**Yoon Sup Choi** *Digital Healthcare Partners, Korea*
FH-02	Blockchain, PHR and digital healthcare	**Eunsol Lee** *Medibloc, Korea*
FH-03	AI-driven precision medicine and drug discovery	**Jaewoo Kang** *Korea University, College of Informatics, Korea*
FH-04	Acquisition of Big Data and its application to the management of chronic disease	**Hajeong Lee** *Seoul National University, Korea*

14:00-15:00 Meet the Expert 1 — MEET 01 — ENG — Small Meeting Room 1

Moderator: **Sang Heon Song** *Pusan National University, Korea*; **Jin Joo Cha** *Korea University, Korea*

MEET 01-01	Using an APP for water and sodium formulas: Discussion with cases of hyponatremia and hypernatremia	**Daniel Batlle** *Northwestern University, USA*

14:00-15:00 Meet the Expert 2 — MEET 02 — ENG — Small Meeting Room 2

Moderator: **Sungjin Chung** *The Catholic University of Korea, Korea*; **Jiwon Lee** *Chungnam National University, Korea*

MEET 02-01	Cyclooxygenase-2 in the kidney	**Raymond C. Harris** *Vanderbilt University*

16:00-18:00 Pediatric Nephrology — PED — ENG ↔ KOR — Room 1

Chair(s): **Kee Hwan Yoo** *Korea University, Korea*; **Hee Gyung Kang** *Seoul National University, Korea*

PED-01	CRRT for children	**Timothy Bunchman** *Virginia Commonwealth University, USA*
PED-02	Maintenance RRT of Korean children	**Il Soo Ha** *Seoul National University, Korea*
PED-03	How to optimize volume status in pediatric RRT patients	**Hee Gyung Kang** *Seoul National University, Korea*
PED-04	Prospective studies in AKI and CRRT of children	**Timothy Bunchman** *Virginia Commonwealth University, USA*

16:00-18:00 Diabetes & Obesity — DIA — ENG ↔ KOR — Room 2

Chair(s): **Hunjoo Ha** *Ewha Womans University, Korea*; **Dae Ryong Cha** *Korea University, Korea*

DIA-01	Reprogramming microbes into live biotherapeutics: Next-generation medicines	**Matthew Wook Chang** *National University of Singapore, Singapore*
DIA-02	TGF-β-induced angiogenesis is a key driver of early DKD pathogenesis	**Kyung Lee** *Icahn School of Medicine at Mount Sinai, USA*
DIA-03	Consequences of obese kidney: The fat-kidney axis	**Se Won Oh** *Korea University, Korea*
DIA-04	Obesity, metabolic syndrome, and CKD	**Seung Hyeok Han** *Yonsei University, Korea*

Detailed Program (May 24)

Detailed Program

16:00-18:00	**APSN-KSN Joint CME Course 2**	CME 02	ENG	Room 3
Chair(s)	**Masaomi Nangaku** *The University of Tokyo, Japan* **Hyeong Cheon Park** *Yonsei University, Korea*			
CME 02-01	**Update in the management of membranous nephropathy in 2019**		**Adrian Liew** *Tan Tock Seng Hospital, Singapore*	
CME 02-02	**Protein energy wasting in chronic kidney disease**		**Jong Ha Park** *University of Ulsan, Korea*	
CME 02-03	**Recent advances in the prevention of hypotension during hemodialysis**		**Sun Woo Kang** *Inje University, Korea*	
CME 02-04	**A novel therapeutic strategy of ADPKD**		**Yoshitaka Isaka** *Osaka University, Japan*	

16:00-18:00	**Oral Communications 7 (Non-dialysis CKD 1)**	OR 07	ENG	Room 4
Chair(s)	**Won Yong Cho** *Korea University, Korea* **Soo Bong Lee** *Pusan National University, Korea*			
	OR 07 NC-01~OR 07 NC-10			

16:00-18:00	**Becoming a New Basic Researcher**	EXP	KOR	Room 5
Chair(s)	**Tae-Hwan Kwon** *Kyungpook National University, Korea* **Won Kim** *Chonbuk National University, Korea*			
EXP-01	**How to get research grant**		**Sang-Ho Lee** *Kyung Hee Univeresity, Korea*	
EXP-02	**How to design research & experiment as beginner**		**Cheol Whee Park** *The Catholic University of Korea, Korea*	
EXP-03	**Experimental techniques for kidney research**		**Eun Hui Bae** *Chonnam National University, Korea*	
EXP-04	**Mouse models to evaluate immune & inflammatory role in human kidney disease**		**Seung Hee Yang** *Seoul National University, Korea*	

18:10-19:10	**Dinner Symposium**	DIN	ENG	Room 1
	Sponsored by **Takeda Pharmaceuticals Korea Co., Ltd** (Takeda Pharmaceuticals Korea CO., LTD.)			
Chair(s)	**Chun Soo Lim** *Seoul National University, Korea*			
DIN-01	**A new era for hypertension treatment with Edarbi/Edarbyclor**		**Hayne Park** *Hallym University, Korea*	

May 25 (Sat)

08:30-10:00	**Glomerular & Tubulointerstitial Disease 2**	GN 02	ENG ↔ KOR	Room 1
Chair(s)	**Kook-Hwan Oh** *Seoul National University, Korea* **Sung Joon Shin** *Dongguk University, Korea*			
GN 02-01	**Contemporary immunosuppressive treatment of membranous nephropathy**		**Sun-Hee Park** *Kyungpook National University, Korea*	
GN 02-02	**Multi-target therapy for treatment of lupus nephritis**		**Zhihong Liu** *Nanjing University, China*	
GN 02-03	**Chloride-sensing of WNK4: a novel mechanism of hypertension in potassium deficiency**		**Chih-Jen Cheng** *Tri-Service General Hospital, Taiwan*	

08:30-10:00	**Hemodialysis 2 - Interventional Nephrology**	HD 02	ENG ↔ KOR	Room 2
Chair(s)	**Yong-Soo Kim** *The Catholic University of Korea, Korea* **Seong Cho** *Sungkyunkwan University, Korea*			
HD 02-01	**How to maximize the efficiency of pre-emptive vascular access correction against thrombosis**		**Hoon Suk Park** *The Catholic University of Korea, Korea*	
HD 02-02	**Duplex ultrasound evaluation of hemodialysis access: A standardized protocol**		**Hyung Seok Lee** *Hallym University, Korea*	
HD 02-03	**Optimal management of central vein disease in hemodialysis patient**		**Anil Agarwal** *Ohio State University, USA*	

08:30-10:00	**CPC - Case 1**		
	Case 1		
Chair(s)	**So Young Jin** *Soonchunhyang University, Korea*		
CPC-01	**Internal Medicine**	**Byung Chul Yu** *Soonchunhyang University, Korea*	
	Clinical Discussion	**Woo Yeong Park** *Keimyung University, Korea*	
	Pathology	**Ahrim Moon** *Soonchunhyang University, Korea*	

Detailed Program

	Case 2		
Chair(s)	**Yeong-Jin Choi**	*The Catholic University of Korea, Korea*	
CPC-02	**Internal Medicine**		**Jung Tak Park** *Yonsei University, Korea*
	Clinical Discussion		**Jung Eun Lee** *Sungkyunkwan University, Korea*
	Pathology		**Beom Jin Lim** *Yonsei University, Korea*

	Case 3		
Chair(s)	**Sun Hee Sung**	*Ewha Womans University, Korea*	
CPC-03	**Internal Medicine**		**Junseok Jeon** *Sungkyunkwan University, Korea*
	Clinical Discussion		**Seung Hyeok Han** *Yonsei University, Korea*
	Pathology		**Ghee-Young Kwon** *Sungkyunkwan University, Korea*

08:30-10:00	**Oral Communications 8 (Acute Kidney Injury 2)**	OR 08	ENG	Room 4
Chair(s)	**Dong-Jin Oh** *Hanyang University, Korea* **Hyo-Wook Gil** *Soonchunhyang University, Korea*			
	OR 08 AKI-01~OR 08 AKI-07			

08:30-10:00	**KSN ESRD Registry Report**	ESRD	KOR	Room 5
Chair(s)	**Dong-Chan Jin** *The Catholic University of Korea, Korea*			
ESRD-01	**KSN ESRD Registry Report 2019**			**Youngsoo Kim** *The Catholic University of Korea, Korea*
ESRD-02	**The development and experiences of informatics system for renal registry in Taiwan – What's able and what's unable?**		ENG	**Shang-Jyh Hwang** *Kaohsiung Medical University, Taiwan*
ESRD-03	**Activity report of task force team for the improvement of KSN ESRD Registry**			**Dong-Ryeol Ryu** *Ewha Womans University, Korea*

09:00-09:45	**KSN Cooperative Study**	COO	KOR	Room 6
Chair(s)	**Dong Won Lee** *Pusan National University, Korea*			
COO-01	**Retrospective and prospective research for the development of practice guideline of IgA nephropathy in Korea**			**Dong-Ryeol Ryu** *Ewha Womans University, Korea*
COO-02	**Development of hemoglobin prediction algorithm and anemia regulation by artificial intelligence in end-stage renal disease**			**Tae-Hyun Yoo** *Yonsei University, Korea*
COO-03	**The optimal management of CKD-MBD in dialysis patients**			**Young Joo Kwon** *Korea University, Korea*

10:00-12:00	**Kidney Transplantation 2 - Risk Assessment and Decision Making in Transplantation**	KT 02	ENG ↔ KOR	Room 1
Chair(s)	**Chul Woo Yang** *The Catholic University of Korea, Korea* **Jong Soo Lee** *University of Ulsan, Korea*			
KT 02-01	**Decision making in donors with metabolic syndrome**			**Cheng-Hsu Chen** *Taichung Veterans General Hospital, Taiwan*
KT 02-02	**Risk assessment and decision making in sensitized recipients**			**Hyosang Kim** *University of Ulsan, Korea*
KT 02-03	**Management of polycystic kidney before and after transplantation**			**Kearkiat Praditpornsilpa** *Chulalongkorn University, Thailand*
KT 02-04	**Risk assessment and decision making in deceased donor kidneys**			**Woo Yeong Park** *Keimyung University, Korea*

10:00-12:00	**Peritoneal Dialysis**	PD	ENG ↔ KOR	Room 2
Chair(s)	**Yong-Lim Kim** *Kyungpook National University, Korea*			
PD-01	**New insights in encapsulating peritoneal sclerosis: It's preventable**			**Masaaki Nakayama** *Tohoku University, Japan*
PD-02	**Lessons from global fluid study**			**Mark Lambie** *Keele University, UK*
PD-03	**PDOPPS – Update**			**Kook-Hwan Oh** *Seoul National University, Korea*
PD-04	**Misperceptions of using PD**			**Dong-Ryeol Ryu** *Ewha Womans University, Korea*

10:00-12:00	**Pathology**	RP	KOR	Room 3
Chair(s)	**Yong-Jin Kim** *Kyungpook National University, Korea* **Kwang-Sun Suh** *Chungnam National University, Korea*			
RP-01	**Diabetic nephropathy**			**Minseob Eom** *Yonsei University, Korea*
RP-02	**Membranous glomerulonephritis**			**Kiseok Jang** *Hanyang University, Korea*
RP-03	**Dysproteinemia-related renal diseases**			**Ji-Youn Sung** *Kyung Hee University, Korea*
RP-04	**Crescentic glomerulonephritis**			**Heounjeong Go** *University of Ulsan, Korea*

Detailed Program

10:00-12:00	**Oral Communications 9 (Dialysis 2)**	OR 09 ENG	Room 4
Chair(s)	**Duk-Hee Kang** *Ewha Womans University, Korea* **Sejoong Kim** *Seoul National University, Korea*		
	OR 09 DL-01~OR 09 DL-10		

10:00-12:00	**KSN-TSN-JSDT Joint Symposium - Diabetic Kidney Disease**	TSN ENG	Room 5
Chair(s)	**Dae Ryong Cha** *Korea University, Korea* **Jin-Shuen Chen** *National Defense Medical Center, Taiwan*		
TSN-01	**Lipid accumulation and glomerular injury in diabetic kidney disease**	**Tae-Hyun Yoo** *Yonsei University, Korea*	
TSN-02	**Diabetic kidney diseases: A Taiwan nephrologist's observations on unmet Issues**	**Jin-Shuen Chen** *National Defense Medical Center, Taiwan*	
TSN-03	**Epigenetic orchestrating embryonic stem cell signaling-based therapeutic platform for diabetic nephropathy: Taiwan's perspective**	**Chun-Liang Lin** *Chang Gung Hospital, Taiwan*	
TSN-04	**Glycemic control in diabetes patients on dialysis in Japan**	**Masanori Abe** *Nihon University, Japan*	

10:00-12:00	**Oral Communications 10 (Inherited Kidney Disease / Fluid, Electrolyte and Acid-Base / Non-dialysis CKD 2)**	OR 10 ENG	Room 6
Chair(s)	**Ji Hong Kim** *Yonsei University, Korea* **Kwon Wook Joo** *Seoul National University, Korea*		
	OR 10 OT-01~OR 10 OT-10		

12:00-13:00	**Luncheon Symposium 5**	LS 05 KOR	Room 1
	Sponsored by **Baxter**		
Chair(s)	**Jong Soo Lee** *University of Ulsan, Korea*		
LS 05-01	**Expanded HD : Confidence Through Experience**	**Hyo-Wook Gil** *Soonchunhyang University, Korea*	

12:00-13:00	**Luncheon Symposium 6**	LS 06 ENG	Room 2
	Sponsored by **Fresenius Medical Care Korea**		
Chair(s)	**Yang Wook Kim** *Inje University, Korea*		
LS 06-01	**From Technology To Therapy Innovation; HighVolumeHDF - Dialysis machine and Dialyser**	**Gerhard Wiesen** *Global Research & Development, FMC, Germany*	

12:00-13:00	**Luncheon Symposium 7**	LS 07 ENG	Room 3
	Sponsored by **Korea Otsuka Pharmaceuticals Co., Ltd**		
Chair(s)	**Hyeong Cheon Park** *Yonsei University, Korea*		
LS 07-01	**Tips in the treatment of ADPKD patients**	**Yoshitaka Isaka** *Osaka University, Japan*	

12:00-13:00	**Luncheon Symposium 8**	LS 08 KOR	Room 4
	Sponsored by **Kyowa Hakko Kirin Korea Co., Ltd**		
Chair(s)	**Chul Woo Yang** *The Catholic University of Korea, Korea*		
LS 08-01	**Anemia management in CKD patients**	**Tae-Hyun Yoo** *Yonsei University, Korea*	

14:00-14:50	**Plenary Lecture 3**	PL 03 ENG ↔ KOR	Room 1&2
Chair(s)	**Yong-Soo Kim** *The Catholic University of Korea, Korea* **Mee Kyung Namgoong** *Yonsei University, Korea*		
PL 03-01	**In search of targeted, mechanism-based therapies for kidney diseases**	**Anna Greka** *Harvard Medical School, USA*	

15:00-17:00	**KSN-ISN Joint Symposium (Inter-Korea Medical Cooperation: Nephrology Perspective)**	IntK ENG ↔ KOR	Room 1
Chair(s)	**Yon Su Kim** *Seoul National University, Korea* **Sung Choon Park** *Seoul National University, Unification Education Research Center, Korea*		
IntK-01	**Preparing for the unification era**	**Jong-Seok Lee** *Sejong Institute, Korea*	
IntK-02	**The Korean peninsula: Our cause for a serious case over 70 years**	**Sin Gon Kim** *Korea University, Korea*	
IntK-03	**The past/present/future of the medical cooperation in nephrology between South Korea and North Korea**	**Sang-Eun Park** *Sam Hospital, Korea*	
IntK-04	**Capacity-building and advocacy to improve access to quality kidney care in developing countries**	**David Harris** *University of Sydney, Austrailia*	
IntK-05	**The future of healthcare and medical education in DPRK**	**Daeyoung Roh** *North Texas Medical Center, USA*	

Detailed Program

15:00-18:00	**KDIGO-KSN Joint Symposium**	KDIGO	ENG ↔ KOR	Room 2
Chair(s)	**Wolfgang Winkelmayer** *Baylor College of Medicine, USA* **Hyeong Cheon Park** *Yonsei University, Korea*			
KDIGO-01	**Pharmacologic treatment of chronic hyperkalemia in CKD**		**Gheun-Ho Kim** *Hanyang University, Korea*	
KDIGO-02	**Insights from a KDIGO controversies conference on potassium management**		**Wolfgang Winkelmayer** *Baylor College of Medicine, USA*	
KDIGO-03	**Care of transition period in Korean patients with CKD**		**Jung Pyo Lee** *Seoul National University, Korea*	
KDIGO-04	**Dialysis initiation**		**Ziad Massy** *University of Picardie Jules Verne, France*	
KDIGO-05	**Current therapies in diabetic kidney disease**		**Hyunjin Noh** *Soonchunhyang University, Korea*	
KDIGO-06	**Anti-glycemic agents in 2019: Beyond glucose**		**Adrian Liew** *Tan Tock Seng Hospital, Singapore*	

15:00-16:30	**KSN-KSCN Joint Symposium (Korean Society of Clinical Nutrition) - Chronic Kidney Disease and Nutrition**	KSCN	KOR	Room 3
Chair(s)	**Dong-Ryeol Ryu** *Ewha Womans University, Korea* **Cheongmin Sohn** *Wonkwang University, Korea*			
KSCN-01	**Nutritional management of chronic kidney disease**		**Sun Moon Kim** *Chungbuk National University, Korea*	
KSCN-02	**Current status of nutritional management of chronic kidney disease in Korea**		**In Seok Lee** *Kyung Hee University Medical Center, Korea*	
KSCN-03	**New form of nutrition education - cooking class for practice of low salt diet**		**Eun Jeong Choi** *Hanyang Women's University, Korea* **Woo Jeong Kim** *Gangnam Severance Hospital, Korea*	

15:00-16:30	**Oral Communications 11 (Transplantation 2)**	OR 11	ENG	Room 4
Chair(s)	**Seungyeup Han** *Keimyung University, Korea* **Sik Lee** *Chonbuk National University, Korea*			
	OR 11 KT-01~OR 11 KT-07			

15:00-16:00	**Dialysis Committee**	DC	KOR	Room 5
Chair(s)	**Myeong Seong Kim** *Gojan Myeong Medical Clinic, Korea*			
DC-01	**2019 Report for hemodialysis center accreditation**		**Young-Ki Lee** *Hallym University, Korea*	
DC-02	**Hemodialysis facility design**		**Hyung Jin Yoon** *Dong Seoul University, Korea*	

15:00-17:00	**"Act on Decisions on Life-Sustaining Treatment" and Hemodialysis**	WDL	KOR	Room 6
Chair(s)	**Jong Soo Lee** *University of Ulsan, Korea* **Yunsuck Koh** *University of Ulsan, Korea*			
WDL-01	**Ethical consideration of current "act on decisions on life-sustaining treatment"**		**Sung Joon Shin** *Dongguk University, Korea*	
WDL-02	**Ethical reflection in the field of nephrology: Hemodialysis as a life-sustaining therapy**		**Yu Ah Hong** *The Catholic University of Korea, Korea*	
Panel Discussion	**End-of-life care after enactment of POLST (physician order for life sustaining treatment): an intensivist's view**		**Chae-Man Lim** *University of Ulsan, Korea*	
Panel Discussion	**Law and culture for End-of-Life**		**Yoon-seong Lee** *Korea Health Personnel Licensing Examination Institute, Korea*	
Panel Discussion	**Maintenance dialysis therapy versus the care of patients with ESRD near the end of life**		**Seung Duk Hwang** *Soonchunhyang University, Korea*	

17:00-18:00	**Shared Decision-Making for Renal Replacement Treatments (Ethics Education)**	ETH	KOR	Room 1
Chair(s)	**Sung Joon Shin** *Dongguk University, Korea* **Sejoong Kim** *Seoul National University, Korea*			
ETH-01	**Ethical way of decision-making: Shared Decision-Making (SDM)**		**Sung Joon Shin** *Dongguk University, Korea*	
ETH-02	**Ethical consideration of SDM for renal replacement treatments in other countries**		**Jae Hyun Chang** *Gachon University, Korea*	
ETH-03	**New Korean model of SDM for renal replacement treatments as an ethical approach**		**Sejoong Kim** *Seoul National University, Korea*	

Detailed Program (May 25)

Detailed Program

16:30-18:30	**Hypertension & Vascular Biology**	HTN	KOR	Room 3
Chair(s)	**Gheun-Ho Kim** *Hanyang University, Korea* **Soo Wan Kim** *Chonnam National University, Korea*			
HTN-01	**Hypertension fact sheet: screening for kidney damage among Korean hypertensive patients**	**Hyeon Chang Kim** *Yonsei University, Korea*		
HTN-02	**Interpretation and adaptation of new AHA guideline for diagnosis and management of hypertension in CKD patients**	**Hong Sang Choi** *Chonnam National University Hospital, Korea*		
HTN-03	**Optimal combination treatment strategy in hypertension**	**Harin Rhee** *Pusan National University, Korea*		
HTN-04	**Special consideration in the management of hypertension among elderly**	**Sung Woo Lee** *Eulji University, Korea*		

16:30-18:00	**Oral Communications 12 (Glomerular and Tubulointerstitial Disorders (CKD) 2)**	OR 12	ENG	Room 4
Chair(s)	**Yun Kyu Oh** *Seoul National Univertisy, Korea* **Ho Jun Chin** *Seoul National University, Korea*			
	OR 12 GN-01~OR 12 GN-07			

16:30-18:00	**KSN-KCCP Joint Symposium (Korean College of Clinical Pharmacy)**	KCCP	KOR	Room 5
Chair(s)	**Bum Soon Choi** *The Catholic University of Korea, Korea*			
KCCP-01	**Clinical consequences and prevention of polypharmacy**	**Bum Soon Choi** *The Catholic University of Korea, Korea*		
KCCP-02	**Current status of Korea ADR relief system**	**Jong Yoon Kim** *Korea Institute of Drug Safety & Risk Management, Korea*		
KCCP-03	**Physician-Pharmacist collaboration in the management of patients with chronic diseases**	**Hyunah Kim** *Sookmyung Women's University College of Pharmacy, Korea*		

May 26 (Sun)

08:30-10:30	**Dialysis Nurse Course 1**	NUR 01	KOR	Room 1
Chair(s)	**Eun Ju Jeong** *Gangnam Severance Hospital, Korea* **Sung Gyun Kim** *Hallym University, Korea*			
NUR 01-01	**How to care the pruritus of HD patients**	**Chang Ook Park** *Yonsei University, Korea*		
NUR 01-02	**The wound management of HD patients (DM foot)**	**Ye-Na Lee** *Korea University, Korea*		
NUR 01-03	**How to manage the Hemodialysis catheter**	**Chang Suk Yi** *Dankook University Hospital, Korea*		
NUR 01-04	**Assessing volume status in hemodialysis patient**	**Byoung Geun Han** *Yonsei University, Korea*		

08:30-10:30	**KSN-KSH Joint Symposium (Korean Society of Hypertension) - Blood Pressure and the Kidney**	KSH	KOR	Room 2
Chair(s)	**Wook Bum Pyun** *Ewha Womans University, Korea* **Yon Su Kim** *Seoul National University, Korea*			
KSH-01	**BP control in resistant hypertension caused by chronic kidney disease**	**Hae Young Lee** *Seoul National University, Korea*		
KSH-02	**Vascular evaluation in CKD patients**	**Chan Joo Lee** *Yonsei University, Korea*		
KSH-03	**How to control BP fluctuation in HD patients**	**Jong Ha Park** *University of Ulsan, Korea*		
KSH-04	**Association of BP components with mortality and CV events in CKD patients**	**Dong-Ryeol Ryu** *Ewha Womans University, Korea*		

08:30-13:30	**Hands-on Session**	Hands	KOR	Room 3
Hands-01	**Basic setting for vascular access Ultrasonography**	**Jin Ho Lee** *Bong Seng Memorial Hospital, Korea*		
Hands-02	**Vascular access ultrasound understanding through clinical cases**	**Seong Cho** *Sungkyunkwan University, Korea*		

- **Ultrasound settings for vascular access/Basic scan modes; B mode, Color & Pulsed wave Doppler scan/Vessel mapping**
- **How to measure flow volume accurately/Finding the culprit lesion/Establishing therapeutic plan**

Hands-on Instructor

Do Hyoung Kim *Hallym University, Korea*	**Eun Jung Kim** *Sahmyook Medical Center, Korea*	**Eun Jung Kim** *Saeheemang Clinic, Korea*
Hoon Suk Park *The Catholic University of Korea, Korea*	**Mina Yu** *Seonam Hospital, Korea*	**Jeonghwan Lee** *SMG-SNU Boramae Medical Center, Korea*

Detailed Program

Hands-on Instructor

Eunyoung Lee *Taeam Clinic, Korea*	**Hyung Seok Lee** *Hallym University, Korea*	**Sun Ryung Choi** *Hallym University, Korea*
Ji Hye Kim *Sahmyook Medical Center, Korea*	**Pyung Joo Park** *Hallym University Sacred Heart Hospital, Korea*	**So Hee Han** *Hallym University Sacred Heart Hospital, Korea*

08:30-10:30 **Dialysis Specialist Physician Course 1 - New Policy in CKD-MBD Management** PHY 01 KOR Room 4

Chair(s) **Rho Won Chun** *Chun and Cho Medical Clinic, Korea*

PHY 01-01	Ca based phosphate binder vs. non Ca base phosphate binder as a first agent for hyperphosphatemia	**Jin Ho Hwang** *Chung-Ang University, Korea*
PHY 01-02	Active vitamin D vs. calcimimetic as a first agent for secondary hyperparathyroidism	**Young-Ki Lee** *Hallym University, Korea*
PHY 01-03	Management of osteoporosis in ESRD patients	**Jung Soo Lim** *Yonsei University, Korea*

11:00-13:00 **Dialysis Nurse Course 2** NUR 02 KOR Room 1

Chair(s) **Bong Ae Shim** *Seoul St. Mary's Hospital, Korea*
Hyung Wook Kim *The Catholic University of Korea, Korea*

NUR 02-01	Hemodialysis in children	**Keum Hwa Lee** *Yonsei University, Korea*
NUR 02-02	Continuous renal replacement therapy	**Dae Young Kim** *Yonsei University Severance Hospital, Korea*
NUR 02-03	On-line hemodialysis & mixed HDF	**Mi Jung Lee** *CHA University, Korea*
NUR 02-04	Individualizing the dialysis in the HD patients	**Jang-Hee Cho** *Kyungpook National University, Korea*

11:00-13:00 **KSN-KES Joint Symposium (Korean Endocrine Society)** KES KOR Room 2

Chair(s) **Tae-Hyun Yoo** *Yonsei University, Korea*

KES-01	Anemia management in CKD/ESRD	**Jae Yoon Park** *Dongguk University, Korea*
KES-02	Diabetes management in primary physicians	**Soo Lim** *Seoul National University, Korea*
KES-03	Tips for management of thyroid diseases in primary care	**Ho-Cheol Kang** *Chonnam National University, Korea*
KES-04	Practical management of CKD-MBD	**Young Youl Hyun** *Sungkyunkwan University, Korea*

11:00-13:00 **Dialysis Specialist Physician Course 2 - Common Problem in Hemodialysis Patients** PHY 02 KOR Room 4

Chair(s) **SungKu Lee** *JD Clinic, Korea*

PHY 02-01	Screening and treatment of depression among patients on dialysis	**Eun Lee** *Yonsei University, Korea*
PHY 02-02	Cancer screening in korean patients with end-stage renal disease	**Kyung Don Yoo** *Dongguk University, Korea*
PHY 02-03	Nutrition education for dialysis patients that doctors need to know	**Jung Joo Lee** *Kyung Hee University Hospital at Gangdong, Korea*

Detailed Program (May 26)

Oral Communications List

May 23 (Thu)

13:00-15:00 Oral Communications 1 (Dialysis 1) OR 01 ENG Room 4

OR 01 DL-01	Plasma endocan level as a predictor of the cardiovascular risk in patients with end-stage renal disease	**Min Hye Kang** *Kyung Hee University Medical Center, Korea*
OR 01 DL-02	The effect of strict volume control assessed by repeated bioimpedance spectroscopy on cardiac function in peritoneal dialysis patients	**Yu Ah Hong** *School of Medicine, The Catholic University of Korea, Korea*
OR 01 DL-03	Prognostic value of serum and dialysate APX-501 in chronic dialysis	**Jin Joo Cha** *Korea University Ansan Hospital, Korea*
OR 01 DL-04	Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent Implantation in Dialysis Patients: a population-based study	**Seokwoo Park** *Seoul National University College of Medicine, Korea*
OR 01 DL-05	Hemoperfusion leads to impairment in hemostasis and coagulation process in patients with acute pesticide intoxication	**Samel Park** *Soonchunhyang University College of Medicine, Korea*
OR 01 DL-06	Timing and appropriate type of dialysis vascular access creation remains a mystery	**Anil Agarwal** *Ohio State University Wexner Medical Center, USA*
OR 01 DL-07	The effect of p-cresyl sulfate on vascular smooth muscle cell proliferation and inflammation	**Shina Lee** *Ewha Womans University Mok-dong Hospital, Korea*
OR 01 DL-08	Emergency presentation in chronic kidney disease on regular hemodialysis attending in Tribhuvan University teaching hospital emergency services	**Tirtha Man Shrestha** *Tribhuvan University, Nepal*
OR 01 DL-09	The prognostic impact of the ratio of the monocyte count to high-density lipoprotein cholesterol in patients with end-stage kidney disease	**Dong Ryul Kim** *The Catholic University of Korea, Incheon St. Mary's Hospital, Korea*
OR 01 DL-10	Obstructive sleep apnea as a risk factor for incident end-stage renal disease: A Nationwide Population-based Cohort Study from Korea	**Hong Sang Choi** *Chonnam National University Hospital, Korea*

15:00-17:00 Oral Communications 2 (Transplantation 1) OR 02 ENG Room 3

OR 02 KT-01	Clinical significance of both De Novo donor specific anti-HLA antibody and kidney donor profile index on post-transplant clinical outcomes in deceased donor kidney transplantation	**Woo-yeong Park** *Keimyung University School of Medicine, Keimyung University Kidney Institute, Korea*
OR 02 KT-02	Clinical significance of De Novo donor specific antibody in kidney transplant recipients with chronic antibody-mediated rejection	**Woo-yeong Park** *Keimyung University School of Medicine, Keimyung University Kidney Institute, Korea*
OR 02 KT-03	Outcomes of HLA-incompatible living donor kidney transplantation compared to deceased donor kidney transplantation or dialysis	**Tai Yeon Koo** *Seoul National University Hospital, Korea*
OR 02 KT-04	Induction of accommodation by anti-complement component 5 antibody-based immunosuppression in ABO-incompatible heart transplantation	**Honglin Piao** *Seoul National University Hospital, Korea*
OR 02 KT-05	Sub-optimal renal recovery and progressive chronic kidney disease after living kidney donation	**Yaerim Kim** *Keimyung University Dongsan Medical Center, Korea*
OR 02 KT-06	Pattern of infections in renal transplant recipients : A perspective from a rural population of South India	**Srinivas Vinayak Shenoy** *Manipal Academy of Higher Education, India*
OR 02 KT-07	Long-term exposure to particulate matter air pollution and the risk of graft failure and mortality in kidney transplant recipients	**Yong Chul Kim** *Seoul National University Hospital, Korea*
OR 02 KT-08	Accessibility and graft outcome according` to economic inequality in South Korea: a widening gap after expansion of insurance coverage	**Sehoon Park** *Seoul National University Hospital, Korea*
OR 02 KT-09	Kidney transplant patients have better health-related quality of life than chronic kidney disease patients with similar renal function	**Jung Hwa Ryu** *Ewha Womans University Medical Center, Korea*
OR 02 KT-10	Development of Tacrolimus-loaded renal homing HGC nanomicelles as a prospective therapeutic for renal diseases	**Chang Seong Kim** *Chonnam National University Medical School, Korea*

15:00-17:00 Oral Communications 3 (Diabetes and Obesity 1) OR 03 ENG Room 4

OR 03 DO-01	β-amyrin rich fraction of ficus racemosa bark alleviates diabetic nephropathy in experimental rats via its antioxidant and anti-inflammatory potential	**Devendrakumar Vaishnav** *Saurashtra University, Rajkot, India*
OR 03 DO-02	Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy	**So-Young Lee** *CHA University, Korea*
OR 03 DO-03	Obesity, sarcopenia, and incident chronic kidney disease	**Wonji Jo** *Severance Hospital, Korea*
OR 03 DO-04	The circulating exosomal microRNA profile in patients with diabetic nephropathy	**Hyoungnae Kim** *Soonchunhyang University Seoul Hospital, Korea*
OR 03 DO-05	Plasma RIPK3 as a biomarker of diabetic nephropathy in type 2 diabetes	**Nam-Jun Cho** *Soonchunhyang University Cheonan Hospital, Korea*
OR 03 DO-06	Placental growth factor deficiency aggravates diabetic nephropathy	**Yaeni Kim** *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*
OR 03 DO-07	Atrial natriuretic peptide prevented lipid-Induced kidney injuries by inhibiting endoplasmic reticulum stress	**Xiaoduo Zhao** *Sun Yat-sen University, China*

Oral Communications List

OR 03 DO-08	Angiotensin II receptor blocker (ARB) alters microRNA profile of circulating exosome in patients with diabetic nephropathy	**Hyo Shik Kim** *Soonchunhyang University Seoul Hospital, Korea*
OR 03 DO-09	Alterations in lipid profile of the aging kidney identified by MALDI imaging mass spectrometry	**Sang Ho Lee** *Kyung Hee University Hospital at Gangdong, Korea*
OR 03 DO-10	Ketogenic diet delays the progression of diabetic nephropathy in db/db Mice	**Woo-yeong Park** *Keimyung University School of Medicine, Keimyung University Kidney Institute, Korea*

May 24 (Fri)

09:00-11:00	**Oral Communications 4 (Glomerular and Tubulointerstitial Disorders (CKD) 1)**	OR 04	ENG	Room 4
OR 04 GN-01	Comparison of the efficacy and safety of combined tacrolimus and low-dose corticosteroid with high-dose corticosteroid in adults with minimal change nephrotic syndrome	**Ho Jun Chin** *Seoul National University Bundang Hospital, Korea*		
OR 04 GN-02	Outcome of membranoproliferative glomerulonephritis (MPGN) and C3 glomerulopathy stratified by new classification	**Young-Bin Son** *Korea University Anam Hospital, Korea University College of Medicine, Korea*		
OR 04 GN-03	Elevated Urinary Mitochondrial DNA Copy Numbers in IgA Nephropathy	**Byung Chul Yu** *Soonchunhyang University Bucheon Hospital, Korea*		
OR 04 GN-04	C3a induces versican V1 overexpression in tubular cells of focal segmental glomerulosclerosis	**Runhong Han** *National Clinical Research Center of Kidney Diseases, China*		
OR 04 GN-05	Environment-Wide Association Study on Chronic Kidney Disease in the National Health and Nutrition Examination Survey (1999–2016)	**Jeonghwan Lee** *SMG-SNU Boramae Medical Center, Korea*		
OR 04 GN-06	Cancer Development and Mortality Differences in Patients with Glomerulonephritis after Renal Biopsy: A Single Center Retrospective Cohort Study	**Hyunjin Ryu** *Seoul National University College of Medicine, Korea*		
OR 04 GN-07	Adverse Outcomes after Non-urological Surgeries in Patients with Chronic Kidney Disease: A Matched Nationwide Study	**Chien-Chang Liao** *Taipei Medical University Hospital, Taiwan*		
OR 04 GN-08	3'UTR Variants of TNS3, PHLDB1, NTN4 and GNG2 Genes are associated with IgA Nephropathy Risk in Chinese Han Population	**Hui Han** *Hainan General Hospital, China*		
OR 04 GN-09	Predictability of MEST-C score on the outcomes of children and adult patients with Henoch-Schölein nephritis	**Donghwan Yun** *Seoul National University Hospital, Korea*		
OR 04 GN-10	Increased susceptibilty of aging kidney to toxic inury	**Su Woong Jung** *Kyung Hee University Hospital at Gangdong, Korea*		

09:00-11:00	**Oral Communications 5 (Diabetes and Obesity 2 / Hypertension and Vascular Biology)**	OR 05	ENG	Room 5
OR 05 DO-01	Evaluation of Antioxidative, Antihyperglycemic and Antithyroidic properties of Cucurbita pepo Peel Extracts on renal disease in Mice.	**Lata Sunhre** *Devi Ahilya Vishwavidyalaya, Indore, India*		
OR 05 DO-02	O-GlcNAcylation of Runx2 is critical for diabetic vascular calcification	**Chang Hyun Byon** *Chonnam National University Hospital, Korea*		
OR 05 DO-03	Intra-individual Variability in High Density Lipoprotein Cholesterol and Risk of End-Stage Renal Disease: A Nationwide Population-Based Study	**Jongho Son** *The Catholic University of Korea, Yeouido St. Mary's Hospital, Korea*		
OR 05 HV-01	Simplified uremic vasculopathy model using induced pluripotent stem cells and uremic toxin mixture	**Hye Ryoun Jang** *Stem cells and Regenerative Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*		
OR 05 HV-02	Clinical manifestations and a RNF213 p.Arg4810Lys variant in pediatric patients with hypertension and Moyamoya disease	**Jeong Yeon Kim** *Samsung Medical Center, Korea*		
OR 05 HV-03	Sex-related differences in the intratubular renin-angiotensin system (RAS) in 2-kidney 1-clip hypertensive rats	**Yang Gyun Kim** *Kyung Hee University Hospital at Gangdong, Korea*		
OR 05 HV-04	The role of L-type Calcium Channels in ureter smooth muscle action potential and its modulation by Nifedipine	**Chitaranjan Mahapatra** *Indian Institute of Technology Bombay, India*		
OR 05 HV-05	Systolic Blood Pressure and Risk of Incident Chronic Kidney Disease: A Nationwide Cohort Study of Ten Million Adults in South Korea	**Cheol Ho Park** *Severance Hospital, Korea*		
OR 05 HV-06	Increasing systolic blood pressure trend is associated with CKD development in subjects without hypertension: The results from the KoGES	**Youngsu Joo** *Severance Hospital, Korea*		
OR 05 HV-07	Ambulatory Blood Pressures in Managing Blood Pressures of Patients with Chronic Kidney Disease	**Hyung Eun Son** *Seoul National University Bundang Hospital, Korea*		

14:00-16:00	**Oral Communications 6 (Acute Kidney Injury 1)**	OR 06	ENG	Room 4
OR 06 AKI-01	Therapeutic challenge of minicircle vector encoding Klotho in animal model	**Sun-Woo Lim** *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*		
OR 06 AKI-02	Role of NLRP3 in rhabdomyolysis-induced acute kidney injury	**Yang Gyun Kim** *Kyung Hee University Hospital at Gangdong, Korea*		
OR 06 AKI-03	Modeling of tacrolimus nephrotoxicity using kidney organoids derived from human iPS cells	**Jin Won Kim** *School of Medicine, The Catholic University of Korea, Korea*		

Oral Communications List

OR 06 AKI-04	PARP inhibitor treatment attenuated renal injury in a murine ischemic AKI model	Kyungho Lee *Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Korea*
OR 06 AKI-05	The Inhibition of Xanthine Oxidoreductase by Febuxostat Ameliorates Oxidative Stress in Contrast Induced Nephropathy through the AMPK-NOXs-HIF-1α Signaling in Mice	Yu Ah Hong *The Catholic University of Korea, Daejeon St. Mary's Hospital, Korea*
OR 06 AKI-06	Identification of key genes and biological pathways associated with ischemia-reperfusion injury in the human kidney using RNA-seq	Meeyoung Park *Pusan National University Hospital, Korea*
OR 06 AKI-07	Anti-CD45RB antibody therapy attenuates renal ischemia-reperfusion injury by inducing regulatory B cells	Sun-Kyung Lee *Seoul National University Hospital, Korea*
OR 06 AKI-08	Change of lung surfactant protein A and D in renal ischemia reperfusion injury	Wook-joon Kim *Soonchunhyang University Cheonan Hospital, Korea*
OR 06 AKI-09	Three-dimensional visualization of renal resident mononuclear cells with clearing in murine model of acute kidney injury	Ju-Young Moon *Kyung Hee University Hospital at Gangdong, Korea*
OR 06 AKI-10	Assessment of nephrotoxicity in mice of herbal medicine containing aristolochic acid	YI QUAN *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*

16:00-18:00	Oral Communications 7 (Non-dialysis CKD 1)	OR 07	ENG	Room 4

OR 07 NC-01	Long term effects of intensive low salt diet education on deterioration of glomerular filtration rate among non-diabetic hypertensive patients with chronic kidney disease	Shin Young Ahn *Korea University Guro Hospital, Korea*
OR 07 NC-02	Optimal blood pressure control in patients with chronic kidney disease	Jee Young Lee *Yonsei University College of Medicine, Korea*
OR 07 NC-03	Urinary renin and angiotensinogen for predicting anti-proteinuric effect of angiotensin receptor blocker	Junseok Jeon *Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*
OR 07 NC-04	Serum Osteoprotegrin Levels are Associated with an Increased Risk of Developing Anemia in Patients with Non-dialysis Chronic Kidney Disease	YOOJU NAM *Severance Hospital, Korea*
OR 07 NC-05	Low bone mass is significantly associated with an Increased Risk of Anemia in Patients with Non-dialysis Chronic Kidney Disease	Seon Yeong Lee *Yonsei University College of Medicine, Korea*
OR 07 NC-06	Glomerular hyperfiltration is associated with high risk of dementia: Nationwide population-based study	Min Woo Kang *Seoul National University Hospital, Korea*
OR 07 NC-07	The effects of periostin on the lipid metabolism in the aged kidney	Jung Nam An *SMG-SNU Boramae Medical Center, Korea*
OR 07 NC-08	Notch Signaling Pathway in High Glucose Induced Mitochondrial Oxidative Damage and Apoptosis in Renal Tubular Epithelial Cells and Its Possible Mechanism	Ying Zhang *Hainan General Hospital, China*
OR 07 NC-09	Cyclo(His-Pro) prevents against oxidative stress-induced renal injury through activating Nrf2-mediated pathway.	Yong Chul Kim *Seoul National University Hospital, Korea*
OR 07 NC-10	PGC-1α inhibits the NLRP3 inflammasome via preserving mitochondrial viability to protect kidney fibrosis	Jong Hyun Jhee *Inha University Hospital, Korea*

May 25 (Sat)

08:30-10:00	Oral Communications 8 (Acute Kidney Injurt 2)	OR 08	ENG	Room 4

OR 08 AKI-01	Postoperative acute kidney injury and intraoperative mean arterial pressure variability – a multi-cohort observational study	Sehoon Park *Seoul National University Hospital, Korea*
OR 08 AKI-02	Perioperative statin use and risk of acute kidney injury following major surgery: a nationwide population-based cohort study	Hoon Young Choi *Yonsei University College of Medicine, Korea*
OR 08 AKI-03	Impact of a novel fluid protocol on electrolytes stability in patients undergoing continuous renal replacement therapy	Song In Baeg *Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*
OR 08 AKI-04	Application of Contrast-Induced Nephropathy Criteria on Fluorescent Angiography: Is Sodium Fluorescein a Possible Cause of Contrast-Induced Nephropathy?	Donghwan Yun *Seoul National University Hospital, Korea*
OR 08 AKI-05	Predictability of Systolic Blood Pressure at Discharge on the Risk of End-Stage Renal Disease after Percutaneous Coronary Intervention	Donghwan Yun *Seoul National University Hospital, Korea*
OR 08 AKI-06	Urinary exosomal microRNA-21 as a marker of scrub typhus associated acute kidney injury	In O Sun *Presbyterian Medical Center, Korea*
OR 08 AKI-07	Impact of aging on long-term renal outcomes following ischemia-reperfusion injury (IRI)	Myung-Gyu Kim *Korea University Anam Hospital, Korea*

Oral Communications List

10:00-12:00	Oral Communications 9 (Dialysis 2)	OR 09	ENG	Room 4	
OR 09 DL-01	Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with Darbepoetin alfa in patient on hemodialysis				Yaerim Kim *Keimyung University Dongsan Medical Center, Korea*
OR 09 DL-02	Effect of medium cut-off dialyzer on middle molecules: one-year experience				Nam-Jun Cho *Soonchunhyang University Cheonan Hospital, Korea*
OR 09 DL-03	Analysis of Associations between Vascular Calcification of Vascular Access, Coronary artery calcium score and Access Survival Using Non-contrast arm CT scan				Hyunsuk Kim *Chuncheon Sacred Heart Hospital, Korea*
OR 09 DL-04	Randomized controlled trial of medium cut-off or high-flux dialyzer on quality-of-life outcomes in maintenance hemodialysis patients				Jeong-Hoon Lim *Kyungpook National University Hospital, Korea*
OR 09 DL-05	Circulating PCSK9 level predicts risk of cardiovascular events death in hemodialysis patients				Ji Yoon Kong *Kyung Hee University Medical Center, Korea*
OR 09 DL-06	Comparison of Vascular Access patency and Patient`s Survival between Native Arteriovenous Fistula and Synthetic Arteriovenous Graft According to Age Group				Hoon Suk Park *The Catholic University of Korea, St. Vincent's Hospital, Korea*
OR 09 DL-07	Clinical effects of a novel medium cut-off dialyzer (THERANOVA®) in hemodialysis patients				Cheol Gu Hwang *Pusan National University Hospital, Korea*
OR 09 DL-08	The prognostic significance of vascular calcification and alkaline phosphatase in patients with end-stage kidney disease				So Yeon Hwang *The Catholic University of Korea, Incheon St. Mary's Hospital, Korea*
OR 09 DL-09	Stroke risk and post-stroke mortality in patients with renal dialysis: two nationwide studies				Yi-Chun Chou *China Medical University Hospital, Taiwan*
OR 09 DL-10	Non-Adherence to Dialysis among Saudi Patients- Causes and Consequences				Abdulla Al-Sayyari *King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia*

10:00-12:00	Oral Communications 10 (Inherited Kidney Disease / Fluid, Electrolyte and Acid-Base / Non-dialysis CKD 2)	OR 10	ENG	Room 6	
OR 10 OT-01	RAPID-ADPKD (Retrospective epidemiologic study of Asian-Pacific patients with rapid Disease progression of Autosomal Dominant Polycystic Kidney Disease): Design and Methods				Hyunjin Ryu *Seoul National University Hospital, Korea*
OR 10 OT-02	The Clinical Characteristics of Advanced Chronic Kidney Disease with Small Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Subgroup Should Be Spotlighted				Soo Whan Jung *Seoul National University College of Medicine, Korea*
OR 10 OT-03	Computational interaction study of Human Angiotensin Converting Enzyme with anticancer and antimicobial peptides in diabetic nephropathy				Chakresh Kumar Jain *Jaypee Institute of Information Technology, India*
OR 10 OT-04	Associations of plasma neutrophil gelatinase-associated lipocalin, anemia, and renal scarring in children with febrile urinary tract infections				Hyung Eun Yim *Korea University Ansan Hospital, Korea*
OR 10 OT-05	Altered expression of renal claudins in rats with metabolic acidosis and hypercalciuria				Il Hwan Oh *Hanyang University College of Medicine, Korea*
OR 10 OT-06	Role of bioelectrical impedance analysis for estimating body water content in hypernatremia patients				Se Hee Yoon *Konyang University Hospital, Korea*
OR 10 OT-07	CARDIOVASCULAR EVENTS AND MORTALITY IN KOREAN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM KNOW-CKD cohorts				Hyunjin Ryu *Seoul National University Hospital, Korea*
OR 10 OT-08	Association of serum uric acid levvel and long-term outcome in chronic kidney disease from the KoreaN Cohort Study for Outcomes in Patients with Chronic Kidney Disease (KNOW-CKD)				Yunmi Kim *Inje University Busan Paik Hospital, Korea*
OR 10 OT-09	Discrepancy between GFR trends from creatinine and cystatin C in patients with chronic kidney disease: Results from the KoreaN Cohort Study of Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD)				Eunjeong Kang *Seoul National University Hospital, Korea*
OR 10 OT-10	Osteoprotegerin is Associated with Development of Coronary Artery Calcification But Not Severity and Progression in Non-dialysis Chronic Kidney Disease: results from the KNOW CKD study				Seon Ha Baek *Hallym University Dongtan Sacred Heart Hospital, Korea*

15:00-16:30	Oral Communications 11 (Transplantation 2)	OR 11	ENG	Room 4	
OR 11 KT-01	Graft immaturity and safety concerns in transplanted human kidney organoids				Sun Ah Nam *School of Medicine, The Catholic University of Korea, Korea*
OR 11 KT-02	Influence of tacrolimus on brain-derived neurotropic factor expression in the hippocampus in diabetic rats				Yoo-Jin Shin *School of Medicine, The Catholic University of Korea, Korea*
OR 11 KT-03	Pancreatic Kallikrein Protects Against Tacrolimus-Induced Pancreatic and Renal Injuries				Jizhe Jin *Yanbian University Hospital, China*
OR 11 KT-04	Assessment of the usefulness of acute rejection specific transcriptomic signatures in a prospective kidney transplantation cohort				Su Woong Jung *Kyung Hee University Hospital at Gangdong, Korea*
OR 11 KT-05	Tertiary lymphoid tissues predict progressive graft dysfunction in kidney transplant recipients				Yu Ho Lee *Bundang CHA General Hospital, Korea*

Oral Communications List

OR 11 KT-06	Comparison of immune cell profiling between human and mouse kidneys	**Seung Seok Han** *Seoul National University Hospital, Korea*
OR 11 KT-07	Effect of conversion from tacrolimus to CTLA4Ig in experimental model of diabetes mellitus	**Kang Luo** *School of Medicine, The Catholic University of Korea, Korea*

16:30-18:00 Oral Communications 12 (Glomerular and Tubulointerstitial Disorders (CKD) 2) OR 12 ENG Room 4

OR 12 GN-01	Glucocorticoid receptor wields chromatin interactions and tunes transcription for podocyte cytoskeleton	**Yuexian Xing** *National Clinical Research Center of Kidney Diseases, China*
OR 12 GN-02	Effectiveness of Coenzyme Q10-Micelle Compared With Coenzyme Q10 On Tacrolimus-Induced Renal Injury	**Sheng Cui** *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*
OR 12 GN-03	Sub-chronic exposure to fine particulate matter results in kidney injury and hypoperfusion.	**Jin Joo Cha** *Korea University Ansan Hospital, Korea*
OR 12 GN-04	A Water-Soluble Extract from Actinidia arguta (PG102) can Inhibit Kidney Fibrosis	**Jeonghwan Lee** *SMG-SNU Boramae Medical Center, Korea*
OR 12 GN-05	L-Carnitine Treatment Attenuates Renal Tubulointerstitial Fibrosis Induced by Unilateral Ureteral Obstruction	**Hui Ying Li** *Yanbian University Hospital, China*
OR 12 GN-06	THE PROGNOSTIC ROLE OF RED CELL DISTRIBUTION WIDTH IN PREDICTING MORTALITY AMONG CHRONIC KIDNEY DISEASE: A META-ANALYSIS STUDY	**Muhamad Fajri Addai** *Johar Baru Primary Health Care, Indonesia*
OR 12 GN-07	FCRL3 and MTMR3 Gene Polymorphisms Associated with IgA Nephropathy risk in the Chinese Han population	**Zhang Daofa** *Hainan General Hospital,Haikou, Hainan, China*

Poster Presentation list

May 24 (Fri)

Acute Kidney Injury — Exhibition Hall, 5F

PAK001	Importance of intracellular water removal during continuous renal replacement therapy in patients with acute kidney injury	**Harin Rhee** *Pusan National University Hospital, Korea*
PAK002	Creatinine-cystatin C Ratio is associated with mortality in ICU patients undergoing continuous renal replacement therapy	**Chan-Young Jung** *Severance Hospital, Korea*
PAK003	Predictive factors for renal outcome in heart transplantation	**Junseok Jeon** *Samsung Medical Center, SungkyunKwan University School of Medicine, Korea*
PAK004	Urinary biomarkers for early prediction of acute kidney injury	**Hee Sun Baek** *Kyungpook National University Hospital, Korea*
PAK005	URINARY CYSTATIN C (UCysC) AS AN EARLY BIOMARKER OF ACUTE KIDNEY INJURY (AKI) IN CRITICALLY ILL PATIENT	**Karthik Balasubramaniam** *Kidney Care Centre, Tirunelveli, India*
PAK006	Cerebro-Renal Syndrome	**Soundarapandian Palanisamy** *Apollo hospitals, Madurai, India*
PAK007	Ceria-Zirconia nanoparticles as an enhanced antioxidant attenuates apoptosis of human kidney proximal tubular epithelial cells in hypoxia	**Se Hee Yoon** *College of Medicine, Konyang University, Korea*
PAK008	Persistent infiltration of M2 macrophages in human acute kidney injury predicts poor renal outcomes	**Kijoon Lim** *Korea University Anam Hospital, Korea*
PAK009	Acute kidney injury following ingestion of oxalic acid (H2C2O4) and potassium permanganate (KMnO4) – A review	**Thilini Wijerathna** *University of Peradeniya, Sri Lanka*
PAK010	Renal damage following self-poisoning with Chlorophenoxy herbicide [2-Methyl-4-chlorophenoxyacetic acid (MCPA)] – A case report	**Thilini Wijerathna** *University of Peradeniya, Sri Lanka*
PAK011	Clinical significance of acute kidney injury in lung cancer patients	**Se Min Cho** *Seoul National University Hospital, Korea*
PAK012	Comorbidities can predict the mortality of acute kidney injury requiring continuous renal replacement therapy: comparison with the Charlson comorbidity index	**Jangwook Lee** *Seoul National University Hospital, Korea*
PAK013	Potential effect of Naringenin against ischemia/reperfusion induced acute kidney injury in rats via Nrf2/HO-1 signaling pathway	**Mahfoozur Rahman** *Sam Higginbottom University of Agriculture, Technology and Sciences, India*

Poster Presentation list

PAK014	Qurecetin-metformin exert protection against diabetes mellitus induced nephropathy in experimental animal via inhibition of DPP-4	**Vikas Kumar** *SIHATS, India*
PAK015	Anti-fibrotic and anti-apoptotic effect of PLGA loaded nano-formulation of Ganoderic acid against cisplatin-induced acute kidney injury in rats via PI3K/Akt/Nrf2 pathway	**Deeksha Chauhan** *United Group of Institution, India*
PAK016	Grafting of Biocompatible and Biodegradable Polymer Aminocellulose Ameliorates the In-vitro and In-vivo Dose Dependent Acute Oral Nephrotoxicity of Customised Trilayer Superparamagnetic Iron-Oxide Nanocarriers (SPIONs) formulated for Drug Delivery Purpose.	**Anas Ahmad** *Institute of Nano Science and Technology (INST), India*
PAK017	Protective Effect of Linalool Against Lipopolysaccharide-Induced Acute Kidney Injury in a Rat Model	**Sahida Naseem** *Sam Higginbottom University of Agriculture, Technology & Sciences, India*
PAK018	Increased delta neutrophil index is associated with in hospital renal survival and mortality in alcoholic ketoacidosis patients	**Jun Young Lee** *Wonju Severance Christian Hospital, Korea*
PAK019	Rhabdomyolysis secondary to the concomitant use of simvastatin and amiodarone in Korea: case report	**Hyun Jin Kim** *Seoul Veterans Hospital, Korea*
PAK020	Clinical importance of renal function in patients needed stem cell transplantation.	**Yu Hyeun Jeon** *Pusan National University Hospital, Korea*
PAK021	Hypoalbuminemia is related with worse kidney outcomes and mortality after coronary artery bypass graft surgery	**Yeonhee Lee** *Seoul National University Hospital, Korea*
PAK022	Clinical usefulness of contrast-enhanced computed tomography in patients with nonobstructive acute pyelonephritis-associated acute kidney injury	**AYOUNG CHO** *Presbyterian Medical Center, Korea*
PAK023	Hyperphosphatemia and Risks of Acute Kidney Injury, End-Stage Renal Disease, and Mortality in Hospitalized Patients	**Hongran Moon** *Seoul National University Hospital, Korea*
PAK024	A case of acute pyelonephritis with acute kidney injury caused by Enterococcus hirae in male patient with benign prostate hyperplasia	**Ju Hwan Oh** *Presbyterian Medical Center, Korea*
PAK025	The Risk Factors for Acute Kidney Injury in Urinary Tract Infection Patients from nursing home in Korea	**Myungah Ha** *The Catholic University of Korea, Bucheon St. Mary's Hospital, Korea*
PAK026	Clinical significances of urinary obstruction in critically ill patients with urinary tract infections s of urinary obstruction in critically ill patients with urinary tract infections	**Jungho Shin** *Chung-Ang University College of Medicine, Korea*
PAK027	The effect of diet on cisplatin-induced nephrotoxicity	**Jisu Kim** *Kyungpook National University School of Medicine, Korea*
PAK028	Gender difference in kidney ischemia-reperfusion injury is associated with the mitochondria quality control	**Min Jung Kong** *Kyungpook National University School of Medicine, Korea*
PAK029	Use of zebrafish for studying chemical induced acute kidney injury and chronic kidney disease	**So Young Lim** *Seoul National University, Korea*
PAK030	Renoprotective effect of carbon monoxide releasing molecule-2 against LPS-induced acute kidney injury	**Md Jamal Uddin** *Ewha Womans University, Korea*
PAK031	Multilevel Regression Analysis about Factors Associated with Chronic Kidney Disease among Patients with Hypertension in Indonesia	**Ayu Rahayu** *Gadjah Mada University, Indonesia*
PAK032	Dysnatremia is associated with acute kidney injury and long-term mortality after coronary artery bypass grafting	**JAE SHIN CHOI** *Hana General Hospital, Korea*

May 25 (Sat)

Acute Kidney Injury — Exhibition Hall, 5F

PAK033	Acute kidney injury sensitivity in diabetic murine model	**Sang Heon Song** *Pusan National University Hospital, Korea*
PAK034	Urosepsis and acute kidney injury after urine alkalization via percutaneous nephrostomy	**Seong Gyu Kim** *Catholic University of Daegu School of Medicine, Korea*
PAK035	The role of Akt1 in murine model of renal ischemia reperfusion injury	**Il Young Kim** *Pusan National University Yangsan Hospital, Korea*
PAK036	Acute Kidney Injury in Traumatic Patients with Coagulopathy	**Orapan Kongsap** *Suratthani Hospital, Thailand*
PAK037	Oral Cyclophosphamide induced Posterior reversible encephalopathy syndrome in Rapidly progressive glomerulonephritis	**Ji Hye Kwak** *Gyeongsang National University Hospital, Korea*
PAK038	PARP activation during cisplatin nephrotoxicity in zebrafish and mice	**Jinu Kim** *Jeju National University School of Medicine, Korea*
PAK039	A case report of biopsy proven bisphosphonate induced acute kidney injury of a patient with kidney transplantation	**Ho Yong Jin** *Chuncheon Sacred Heart Hospital, Korea*
PAK040	Protective effect of alpha 1-antitrypsin on renal ischemia-reperfusion injury in a mouse model	**Kye Hwa Jeong** *Kyungpook National University Hospital, Korea*

Poster Presentation list

PAK041	Case Study: Effectiveness of "Ganyong" (Canna edulis Kerr), A Traditional Herb Used by Mandar People, West Sulawesi, Indonesia to Cure Kidney Inflammation Diseases and Hypertension	**Jumriani Jumriani** *Islamic Boarding School Al-Ikhlas, Indonesia*
PAK042	The Interactive Effects of Input and Output on Managing Fluid Balance in Patients with Acute Kidney Injury Requiring Continuous Renal Replacement Therapy	**Jong Hyun Jhee** *Inha University Hospital, Korea*
PAK043	Renal Tubular GLP-1 receptor is increased in early sepsis which reduced in CKD and sepsis induced kidney injury	**Jae Hyun Choi** *Hana General Hospital, Korea*
PAK044	Membranoproliferative glomerulonephritis and severe acute tubular necrosis in pulmonary tuberculosis	**Jong In Choi** *Chosun University Hospital, Korea*
PAK045	The stabilizing effect of dipeptidyl peptidase-4 inhibitors on the epithelial barrier in the colistin-induced tubular injury	**Ji Young Ryu** *Seoul National University Bundang Hospital, Korea*
PAK046	Postoperative acute kidney injury in patients with advanced chronic kidney disease; Incidence, risk factors	**Hyun Seop Cho** *Gyeongsang National University Hospital, Korea*
PAK047	Hypoalbuminemia is related with short- and long-term mortality in patients undergoing continuous renal replacement therapy	**Jong Joo Moon** *Seoul National University Hospital, Korea*
PAK048	Anti-apoptotic effects of green tea extract and gemigliptin on tacrolimus-induced nephropathy in mice	**BYUNG CHUL SHIN** *Chosun University Hospital, Korea*
PAK049	Cyclo(His-Pro) protects against gentamicin-induced cell apoptosis and cisplatin-induced acute kidney injury through inhibiting p53-mediated apoptotic pathway	**Jong Joo Moon** *Seoul National University Hospital, Korea*
PAK050	RISK FACTOR HYPERTENSION, DIABETES MELLITUS, CONSUMTING HERBAL MEDICINE AND FACTORS ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN INDONESIA	**Ramlah Ramlah** *Gadjah Mada University, Indonesia*
PAK051	PREDICTORS OF POOR OUTCOME IN CHILDREN WITH TYPICAL HEMOLYTIC UREMIC SYNDROME	**Marina Khvan** *Nazarbayev University School of Medicine, Kazakhstan*
PAK052	Mechanism of Piperacillin/Tazobactam nephrotoxicity	**Jihyun Yang** *Korea University Anam Hospital, Korea*
PAK053	Effect of Cefepime drug dosing by cystatin C based eGFR	**Jin Ho Hwang** *Chung-Ang University Hospital, Korea*
PAK054	Nutritional status affects the risk of contrast induced nephropathy after percutaneous coronary intervention.	**Miyeun Han** *Pusan National University Hospital, Korea*
PAK055	Albumin is a Prognostic Factor in Patients with Acute Kidney Injury receiving Continuous Renal Replacement Therapy	**Jae Hyuc Choi** *Kosin University Gospel Hospital, Korea*
PAK056	Acute kidney injury (AKI) in obstructive uropathy	**Bong Gyun Sun** *Korea University Anam Hospital, Korea*
PAK057	Vulnerable patient with chronic kidney disease in upper gastrointestinal bleeding.	**Tae Won Lee** *Gyeongsang National University Hospital, Korea*
PAK058	The effects of high fat and high salt diet on early renal outcome in ischemic AKI	**Minjung Kim** *Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*
PAK059	STUDY OF ANALYSIS VARIOUS RISK FACTORS OF KIDNEY STONE (Nephrolithiasis) IN INDONESIAN COMMUNITY	**Anna Farhana** *Universitas Gadjah Mada, Indonesia*
PAK060	Low mean blood pressure as a risk factor of short-term and long-term mortality in patients undergoing continuous renal replacement therapy	**Yaerim Kim** *Keimyung University Dongsan Medical Center, Korea*
PAK061	Malaria and AKI: A review of adverse prognostic factors	**MAYOOR PRABHU** *KASTURBA MEDICAL COLLEGE MANGALORE, India*
PAK062	FACTORS RELATED TO THE QUALITY OF LIFE OF CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING HEMODIALYSIS IN SEVERAL HOSPITALS IN INDONESIA	**Destriyani Destriyani** *Pambusuang primary health center, Polewali Mandar, West Sulawesi, Indonesia*
PAK063	Recurrence rate of rhabdomyolysis among healthy adults in a military hospital: a prospective observational pilot study	**YongJin Yi** *Korean Armed Forces Capital Hospital, Korea*
PAK064	Toxicodendron vernicifluum extract ameliorate renal injury in unilateral ureteral obstruction mice.	**Da Bi Kim** *Chungnam National University School of Medicine, Korea*

May 24 (Fri)

Inherited Kidney Disease (Pediatric nephrology) — Exhibition Hall, 5F

PIK001	Features of Autosomal Recessive Alport Syndrome: A Systematic Review	**Jiwon Lee** *Chungnam National University Hospital, Korea*
PIK002	Whole-Exome Sequencing Detected Mutations in Pediatric Patients with Atypical Hemolytic Uremic Syndrome in Taiwan	**Min-Hua Tseng** *Chang Gung Memorial Hospital, Chang Gung University, Taiwan*
PIK003	Functional Evaluation of an Ectopic Supernumerary Kidney in Pelvis	**Aylin AKBULUT** *Ankara Training and Application Hospital, University of Health Sciences, Turkey*
PIK004	GENOTYPE-PHENOTYPE ANALYSES OF PEDIATRIC PATIENTS WITH PAX2 MUTATIONS	**JI HYUN KIM** *Seoul National University Hospital, Korea*
PIK005	A Rare Clinical Case Study of Calculus Induced Hydroureteronephrosis Obstructive Syndrome in a Patient with Two Separate Pelvicalcyeal System in Right Side with Bifid Ureter	**Anil Gautam** *Research Centre for Applied Science and Technology, Nepal*

Poster Presentation list

May 24 (Fri)

Diabetes and Obesity — Exhibition Hall, 5F

PDO001	A Case Control Study on Body Composition of Patients of Type 2 Diabetes Mellitus	**Prakash Mathiyalagen** *Indira Gandhi Medical College & Research Institute, Puducherry, India*
PDO002	Preparation and characterization of antidiabetic sulfonylureas plus metformin loaded polymeric nanoparticles	**Janki Prasad Rai** *School of pharmacy, LNCT University, Bhhopal, India*
PDO003	Association of glycemic control with kidney outcome and mortality in CKD patients with Type 2 diabetes: The results from the KNOW-CKD	**Youngsu Joo** *Severance Hospital, Korea*
PDO004	Influential effects of Momordica charantia fruit extract on glib-enclamide against alloxan- induced diabetic mice	**NEHA SHARMA** *DEVI AHILYA UNIVERSITY INDORE, India*
PDO005	Therapeutic effects of Dipeptidyl peptidase –IV inhibitors and antioxidant properties on kidney from Trigonella foenum for treatment of type 2 diabetes mellitus in rat; in-vivo; in-silico	**ANAND KRISHNA SINGH** *DEVI AHILYA UNIVERSITY INDORE, India*
PDO007	Dehydration May Be a Novel Risk Factor of Insulin Resistance and Poor Body Fat Distribution	**Hyang Ki Min** *Eulji General Hospital, Korea*
PDO008	Type 2 Diabetes Mellitus Risk Factors Assessment in Bangkok Mass Transit System Public Company Limited [BTSC] personnel, Bangkok, Thailand.	**Thanapol Pattanamahin** *Bangkok Mass Transit System Public Company Limited [BTSC], Thailand*
PDO009	Novel 1,3,5-triazine derivatives exert protective action against diabetes induced nephropathy in experimental animal via inhibition of DPP-4	**Udaya Pratap Singh** *Sam Higginbottom University of Agriculture, Technology & Sciences, India*
PDO010	Customized polymeric core-shell nanocarrier formulation mediated naringenin delivery for the treatment of diabetes-induced nephropathy in streptozotocin-induced diabetic model.	**Anas Ahmad** *Institute of Nano Science and Technology (INST), India*
PDO011	EVALUATION OF ANTIDIABETIC AND HYPOLIPIDEMIC ACTIVITY OF CEDRUS DEODARA AND EMBELIA RIBES WITH THEIR SYNERGISTIC EFFECTS	**SOURABH JAIN** *Bhagyoday Tirth Pharmacy College, India*
PDO012	Antidiabetic activity of green synthesized silver nanoparticles using Madhuca longifolia streptozotocin-induced diabetic rats	**Manvendra Singh** *AKTU, HMFA MIET, India*
PDO013	Predictive power of Random Blood Sugar (RBS) in comparison with the Glycosylated Hemoglobin (HbA1c) for deterioration of kidney functions in patients of diabetes	**Jay Karan** *All India Institute of Medical Sciences, Jodhpur, India*
PDO014	PEGylated Glucose Triggered Liposomes for Insulin Delivery	**Mani Bhargava** *Signa College of Pharmacy, India*
PDO015	Subclinical Relationship Between Atheroselerosis and Cystatin C in Patients with diabets Type 2	**Ganga Dulal** *ASUNTA Medicare Hospital pvt ltd, Nepal*
PDO016	Intranasal delivery of insulin for the restoration of memory signaling in Alzheimer disease	**Parul Bhargava** *GTB Hospital, India*
PDO017	Colon Specific Delivery of Insulin loaded Colloidosomes based on pH-dependent polymer	**Nikhil Kapoor** *Himalayan University, India*
PDO018	Preparation and Characterization of Polymeric Nanoparticles for Sustained Delivery of Insulin	**Mani Bhargava** *Signa College of Pharmacy, India*
PDO019	Diabetes complications severity index and glycemic control assessment in recently diagnosed type 2 diabetes for a period of 5 years.	**Dexton Johns** *Zain Clinical Research, India*
PDO020	Oral insulin delivery via anchored PLGA nanoparticles	**Saurabh Bhargava** *United Institute of Pharmacy, India*

May 25 (Sat)

Diabetes and Obesity — Exhibition Hall, 5F

PDO022	Metabolic syndrome of Treatment in Hypokaloric Diet Exogenous constitutional obesity.	**Ganga Dulal** *ASUNTA Medicare Hospital pvt ltd, Nepal*
PDO023	SILYMARIN AND METFORMIN COMBINATION ATTENUATES DIABETIC NEPHROPATHY THROUGH ITS ANTIOXIDANT ACTIVITY	**Vishal Airao** *Saurashtra University, Rajkot, Gujarat, India*
PDO024	BENEFICIAL ROLE OF CAFFEIC ACID ON DIABETIC NEPHROPATHY ASSOCIATED WITH TYPE-I DIABETES MELLITUS IN RATS	**Trupesh Pethani** *Saurashtra University, Rajkot, Gujarat, India*
PDO025	Targeted Delivery of Glyburide Loaded Enteric Coated Gelatin Microspheres for Effective Management of Diabetes Mellitus	**Shiv Kumar Prajapati** *Bhagyoday Tirth Pharmacy College, Sagar, India*
PDO026	Frequency of non-alcoholic fatty liver disease and renal impairment in Helicobacter Pylori infected dyspeptic patients, experience from a developing country.	**Hafiz Abdul Basit Siddiqui** *Aga Khan University Hospital, Pakistan*
PDO027	Tswana traditional health practitioners perspectives on the management of diabetes and hypertension:a qualitatitive study using focus group discussions.	**Ebenezer Frimpong** *University of Kwa Zulu-Natal, South Africa*
PDO028	Klotho effects on lipotoxicity-induced podocyte injury	**Jeong Suk Kang** *Soonchunhyang University Cheonan Hospital, Korea*
PDO029	Formulation and Evaluation of Anti Diabetic Polyherbal Formulations In Alloxan Induced Diabetic Rats	**Vikas Jain** *School of pharmacy, Carrier Point University Kota, India*

Poster Presentation list

PDO030	Evaluation of antidiabetic activity of biologically synthesized silver nanoparticles using Ficus carica in alloxan-induced diabetic rats	**Deepika Jain** *SRG Hospital and Medical College, India*
PDO031	Atherosclerotic Cardiovascular Disease Risk Stratification using lipid profiles in Diabetes and Chronic Kidney Disease: a nationwide population-based study from Korea	**Yeonhee Lee** *Seoul National University Hospital, Korea*
PDO032	RIPK3 KO ameliorates emotional functions in mice with diabetic kidney disease	**Hyun Bin Choi** *Soonchunhyang University College of Medicine, Korea*
PDO033	Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus	**In Hee Lee** *Daegu Catholic University School of Medicine, Korea*
PDO034	Mathematical Modeling and Numerical Simulations of Diabetes Mellitus without Genetic Factors using Treatments	**Rifaldy Fajar** *Yogyakarta State University, Indonesia*
PDO035	Spexin, is it another bystander or an active regulator in diabetic kidney disease?	**Jin Joo Cha** *Korea University Ansan Hospital, Korea*
PDO036	RISK FACTOR AND CONSEQUENCES OF CHILDHOOD OBESITY IN INDONESIA	**Nuraliah Nuraliah** *West Sulawesi University, Indonesia*
PDO037	The Role of Oxidative Stress and Antioxidants in Diabetic Complications	**Sachin Jain** *Teva API India Ltd, India*
PDO038	CENTRAL DIABETES INSIPIDUS IN SPECIAL CONDITION: INTERESTING CASE	**Astried Indrasari** *Hasan Sadikin Hospital, Bandung, Indonesia, Indonesia*
PDO039	Therapeutic efficacy of Ayurvedic formulations in STZ induced diabetic Wistar rats	**Pramod Singh** *DAVV Indore, India*
PDO040	Protective effects of a polyherbal preparation on fasting glucose, lipid and renal function in type 2 diabetes subjects with metabolic syndrome	**DHANANJAY YADAV** *YEUNGNAM UNIVERSITY, Korea*

May 24 (Fri)

Dialysis — Exhibition Hall, 5F

PDL001	Comparison of Actual Dietary Intakes in Hemodialysis Patients:A Prospective Observational Study	**JIEUN Lee** *Ewha Womans University Mokdong Hospital, Korea*
PDL002	Use of blood temperature monitor for surveillance of vascular access in maintenance hemodialysis: Comparison with duplex ultrasonography hemodialysis patients	**Jun Young Lee** *Wonju Severance Christian Hospital, Korea*
PDL003	Effects of initial hypoalbuminemia on the longitudinal changes of residual renal function and peritoneal membrane in incident peritoneal dialysis patients; single center, long term follow up study	**Yu Hyeun Jeon** *Pusan National University Hospital, Korea*
PDL004	The Effect of Treatment Parameters on Achieving High Convective Volume in Post-dilution Online Hemodiafiltration	**Hye-Jin Na** *Konkuk University Medical Center, Korea*
PDL005	Clinical relevance of fluid volume status assessment by bioimpedance analysis using BCM in children on maintenance dialysis.	**Peong Gang Park** *Seoul National University Hospital, Korea*
PDL006	Outdoor carbon monoxide with the risk of mortality of ESRD patients: Comparison the results of control selection in the case-crossover designs	**Yong Chul Kim** *Seoul National University Hospital, Korea*
PDL007	The Assessment of Seasonal variation for Potassium level in Hemodialysis Patients using DialysisNet	**Yunmi Kim** *Inje University Busan Paik Hospital, Korea*
PDL008	Changes in body composition in long-term peritoneal dialysis patients	**Seok Hui Kang** *Yeungnam University Medical Center, Korea*
PDL009	Indoxyl sulfate induced apoptosis in C2C12 cells	**Jung Yoon Heo** *Yeungnam University Medical Center, Korea*
PDL010	Prognostic factors for the percutaneous transluminal coronary angiography in chronic hemodialysis patients	**Byounghwi Ko** *Severance Hospital, Korea*
PDL011	Rate of Advanced Chronic Kidney Disease Patients Undergoing Transradial Approach for Coronary Intervention	**LO-YI HO** *Kwong Wah Hospital, Hong Kong, China*
PDL012	It is time to consider individualized treatment goal for anemia in ESRD	**Shin Young Ahn** *Korea University Guro Hospital, Korea*
PDL013	Hepcidin, iron status, and mineral metabolism in peritoneal dialysis patients	**Hyo Jin Kim** *Dongguk University College of Medicine, Korea*
PDL014	Factors affecting selection of dialysis modality in elderly patients with chronic kidney disease: prospective cohort study of Korea	**Inryang Hwang** *Kyungpook National University Hospital, Korea*
PDL015	Vascular calcification and incident fracture in patients with end-stage kidney disease	**Yun Jung Nam** *The Catholic University of Korea, Incheon St. Mary's Hospital, Korea*
PDL016	READJUSTMENT OF OPTIMAL DRY BODY WEIGHT IS IMPORTANT IN HEMODIALYSIS PATIENTS TRANSFERRED BETWEEN ARTIFICIAL KIDNEY UNITS	**Mun Jang** *Yemidam Hospital, Korea*
PDL017	Impact of Chronic Kidney Disease on Mortality: A Nationwide Cohort Study	**Kyeong Min Kim** *Eulji University School of Medicine, Korea*

Poster Presentation list

PDL018	Fracture risk in chronic kidney disease: a Korean population-based cohort study	**Young Eun Kwon** *Myongji Hospital, Hanyang University College of Medicine, Korea*
PDL019	Suledoxide use as circuit anticoagulant in Continuous Renal Replacement Therapy	**Kristina Alolod** *St. Lukes Medical Center, Philippines*
PDL020	Prevalence and Clinical Characteristics of Saudi Dialysis Patients with or without Positive Family Histories of Kidney Disease.	**Abdulla Al-Sayyari** *King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia*
PDL021	EFFICACY OF MEDIUM CUT-OFF DIALYZER AND COMPARISON WITH STANDARD HIGH-FLUX HEMODIALYSIS AND PREDILUTION ONLINE HEMODIAFILTRATION	**Tae Hoon Kim** *Gangnam Severance Hospital, Korea*
PDL022	Multidisciplinary care in case with Encapsulating Peritoneal Sclerosis	**Ka Lok Chan** *United Chrisitan Hospital, Hong Kong*
PDL023	Estimation of precise dry body weight using bioimpedance analysis in patients with hemodialysis	**Harin Rhee** *Pusan National University Hospital, Korea*
PDL024	Correlation between nutritional markers and phase angle in patients with end-stage renal disease on hemodialysis	**In Hee Lee** *Daegu Catholic University School of Medicine, Korea*
PDL025	Caregiver's quality of life and its predictors in hemodialysis patient	**Seong Gyu Kim** *Catholic University of Daegu School of Medicine, Korea*
PDL026	Mycobacteria Other Than Tuberculosis (MOTT) infection in peritoneal dialysis, a local centre experience	**KA LOK CHAN** *United Christian Hospital, Hong Kong, Hong Kong*
PDL027	Current status and outcomes of vascular access in elderly hemodialysis patients in Korea: Analysis based on a Health Insurance Database	**Cheolsu Kim** *Hallym University Sacred Heart Hospital, Korea*
PDL028	Posttraumatic stress symptoms in hemodialysis patients with MERS-CoV exposure	**Juhee Kim** *Kangnam Sacred Heart Hospital, Korea*
PDL029	Severe mental change in hemodialysis patients with end-stage renal disease without any abnormality in brain imaging	**Hae Ri Kim** *Chungnam national university hospital, Daejeon, Republic of Korea, Korea*
PDL030	Impacts of coronary artery calcification on intradialytic blood pressure patterns in patients receiving maintenance hemodialysis	**JIIN MOON** *Chung-Ang University Hospital, Korea*
PDL031	Association of Interdialytic Weight Gain with Dialysis Malnutrition Score among Hemodialysis Patients in Universitas Gadjah Mada Hospital Yogyakarta-Indonesia	**Elsa Mukti Atmaja** *Universitas Gadjah Mada, Indonesia*
PDL032	The comparison of the usefulness between Low dose and Standard dose adrenocorticotropin (ACTH) stimulation test in peritoneal dialysis patients	**JIWON RYU** *Cheju Halla General Hospital, Korea*
PDL033	Serum calcium change during 3 months in hemodialysis patients treated with denosumab	**Heeryong Lee** *Maryknoll Medical Center, Korea*
PDL034	Sleep Apnea Severity is significantly associated with Volume Overload and Mortality in Patients with Peritoneal Dialysis; Prospective Cohort study	**Ea Wha Kang** *National Health Insurance Service Ilsan Hospital, Korea*
PDL035	The effect of aspirin on preventing primary vascular access dysfunction in the incident hemodialysis patients	**Chan Ho Kim** *Catholic Kwandong University International St. Mary's Hospital, Korea*
PDL036	Low diastolic blood pressure independently predicts major cardiovascular events in prevalent dialysis patients.	**Eun Jin Bae** *Gyeongsang National University Changwon Hospital, Korea*
PDL037	The association of vascular access with mortality and hospitalization in Korean incident hemodialysis patients.	**Gang Jee Ko** *Korea University Guro Hospital, Korea*
PDL038	Comparison of the Effects of the Type of Hemodiafiltration and Citrate Dialysate on the Nutritional Parameters in Chronic Hemodialysis Patients	**HYUK HO KWON** *DR. Kwon's Hemodialysis Clinic,LBL Clinical Research Institute, Korea*

May 25 (Sat)

Dialysis — Exhibition Hall, 5F

PDL039	Intestinal tuberculosis simulating colon cancer in a patient with end-stage renal disease	**In Hee Lee** *Daegu Catholic University School of Medicine, Korea*
PDL040	Salvage of immature brachiocephalic fistula with extrinsic compression	**Sangeon Gwoo** *MH Yeonse hospital, Korea*
PDL041	Denosumab for Osteoporosis Treatment in Hemodialysis Patients : A Single-Center Experience	**Sangeon Gwoo** *MH Yeonse Hospital, Korea*
PDL042	Alterations of structural topology in patients with end-stage renal disease : Evidence from a graph theoretical analysis based on DTI	**YOO JIN LEE** *Inje University Haeundae Paik Hospital, Korea*
PDL043	The association between the swelling of the median nerve and carpal tunnel syndrome in patients with short-term hemodialysis.	**June Hyun Kim** *Pusan National University Yangsan Hospital, Korea*
PDL044	Bioelectrical Impedance Analysis to Predict Outcomes in Hemodialysis Patients	**MinSung Lee** *Soonchunhyang University Bucheon Hospital, Korea*

Poster Presentation list

PDL045	Association of Malnutrition and Quality of Life of Hemodialysis Patients	Kristianne Rachel Medina - Liabres *University of Santo Tomas Hospital, Philippines*
PDL046	Preemptive PTA to maintain adequate dialysis blood flow for severe obese patients with BMI> 40	Jin Ho Lee *Bongseng Hospital, Korea*
PDL047	Experience of Bimodal dialysis: peritoneal dialysis in combination with once weekly hemodialysis	Yeong Hoon Kim *Inje University Busan Paik Hospital, Korea*
PDL048	Clinical significance of urinary sodium excretion on residual renal function in patients with peritoneal dialysis	Yumi Yang *Chungbuk National University Hospital, Korea*
PDL049	The peritonitis, hospitalization and mortality rate in patients starting with incremental peritoneal dialysis: a propensity score matching study	Won Suk An *Dong-A University Hospital, Korea*
PDL050	Serum S100B represents a biomarker for cognitive impairment in patients with end-stage renal disease	Myungjun Seong *Inje University Haeundae Paik Hospital, Korea*
PDL051	The Impact of Comorbidity Index on The Association between Vascular Access type and Clinical Outcomes among Elderly Patients Undergoing Hemodialysis	Jong Hyun Jhee *Inha University Hospital, Korea*
PDL052	Quantitative Nutrient Intake and Dietary Diversity Score of Hemodialysis Patients at Dr. Sardjito Hospital, Jogjakarta, Indonesia	Pinka Cahyati Wibowo *Sardjito Hospital, Indonesia*
PDL053	Peritoneal Dialysis Does not Increase a Risk of Acute Cholecystitis Than Hemodialysis: a Nationwide Population Based Cohort Study	Soon Kil Kwon *Chungbuk National University College of Medicine, Korea*
PDL054	The Expression of NFATc1 Is Influenced by Indoxyl Sulfate through Aryl Hydrocarbon Receptor to Effect Osteoclasts Proliferation and Differentiation	Wen-Chih Liu *Tungs' Taichung Metro Harbor Hospital, Taiwan*
PDL055	Hemoglobin and Albumin Level as Clinical Indicators of Dietary Quality of Maintenance Hemodialysis Patient	Yuni Aminarti *Sardjito Hospital, Indonesia*
PDL056	Massivesubcutaneous calcification in HD	Hyun Woo Kim *Chosun University Hospital, Korea*
PDL057	recurrent subcutaneous and vascular calcification in CAPD patient	Jong Hoon Chung *Chosun University Hospital, Korea*
PDL058	Effects of Online hemodiafiltration on various parameters in patients with end-stage renal disease	Hye Yun Jeong *Bundang CHA General Hospital, Korea*
PDL059	Increasing burden of very-elderly patients with hemodialysis in Korea	Kyoung Sook Park *National Health Insurance Service Ilsan Hospital, Korea*
PDL060	A comparative assessment of cost-effectiveness of dialysis modalities in the Asia-Pacific region	Md Salman Hussain *Jamia Hamdard, India*
PDL061	Bleeding risk associated with warfarin use in hemodialysis patients with co-morbid atrial fibrillation patients: A meta-analysis	Md Sarfaraj Hussain *Sanskriti University, India*
PDL062	Laparoscopic salvage of peritoneal dialysis catheter with omental wrapping: single center experience	Youn Su Lee *Yeungnam University Medical Center, Korea*
PDL063	Fungal peritonitis in peritoneal dialysis patients: a single center experience	Youn Su Lee *Yeungnam University Medical Center, Korea*
PDL064	Outcomes of surgical management of encapsulating peritoneal sclerosis: case series from single center in Korea	Jung Hwa Ryu *Ewha Womans University Medical Center, Korea*
PDL065	Association of Continuous Renal Replacement Therapy Duration and the outcome of Patients in Intensive Care Units	Ha Nee Jang *Gyeongsang National University Hospital, Korea*
PDL066	The location of the double lumen short term catheter for continuous renal replacement therapy does not affect the patient's short term outcome	Ha Nee Jang *Gyeongsang National University Hospital, Korea*
PDL067	Efficacy and Safety of High-volume Hemofiltration (HVHF) in patients with Septic Shock and Acute Kidney Injury: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	Sherida Edding *St. Luke's Medical Center - Global City, Philippines*
PDL068	The association of dialysis adequacy, body mass index, and mortality among hemodialysis patients	YUNTAC LIM *Samsung Changwon Hospital, Korea*
PDL069	Effect of Probiotics Supplementation on Inflammatory Monocytes and Regulatory T Cells in Hemodialysis Patients	Eunho Choi *Korea University Anam Hospital, Korea*
PDL070	Green dialysate and dudenal perforation in a peritoneal dialysis patient	Hee Yeoun Kim *Bongseng Hospital, Korea*
PDL071	Cell-free mitochondrial DNA in patients on hemodialysis	Su Woong Jung *Kyung Hee University Hospital at Gangdong, Korea*
PDL072	Intradialytic metabolic alkalosis is not associated with intradialytic hypotension.	Seon Ha Baek *Hallym University Dongtan Sacred Heart Hospital, Korea*
PDL073	Two cases of successful treatment with MARS in hepatorenal syndrome: a bridge therapy for liver transplantation	Won Kim *Chonbuk National University Medical School, Korea*
PDL074	Deep Neural Networks Trained on Dialysis Features Can Predict Mortality in ESRD Patients	Ji Won Min *The Catholic University of Korea, Bucheon St. Mary's Hospital, Korea*
PDL075	A change in the quality of life after the use of 'theranova'	Dong Yeol Lee *Bongseng Hospital, Korea*

Poster Presentation list

May 24 (Fri)

Fluid, Electrolyte and Acid-Base — Exhibition Hall, 5F

PFL001	A Case of Transient Central Diabetes Insipidus Caused By Hyponatremic Encephalopathy : A Case Report	**Jong Sun Yeom** *Hallym University Dongtan Sacred Heart Hospital, Korea*
PFL002	Case of Transient Visual loss due to Metformin-associated lactic acidosis (MALA)	**Jae Wan Jeon** *Chungnam National University Hospital, Korea*
PFL003	Proteomic Analysis of Urinary Exosomes in Patients with Gitelman Syndrome	**Chih-Chien Sung** *Tri-Service General Hospital, National Defense Medical Center, Taiwan*
PFL004	Acute and Chronic complications of Lithium Toxicity: A Case Report	**Yumi Czarina Ong- Cruda** *Makati Medical Center, Philippines*
PFL005	Genotype, Phenotype and Follow-up in Taiwanese Patients with Congenital Nephrogenic Diabetes Insipidus	**Min-Hua Tseng** *Chang Gung Memorial Hospital, Chang Gung University, Taiwan*

May 24 (Fri)

Glomerular and Tubulointerstitial Disorders (CKD) — Exhibition Hall, 3F

PGN001	Moringa Seeds Extract (Moringa oleifera, Lam.) inhibits the progression of kidney impairment through increasing renal Superoxide Dismutase (SOD) expression and lowering renal biomarkers level in metabolic syndrome rat model	**Indah Sagitaisna Putri** *Faculty of Medicine, Sebelas Maret University, Indonesia*
PGN002	The high dietary PUFA Is Associated with lower prevalence of chronic kidney disease in population-based cohort subjects.	**Shinchan Kang** *Severance Hospital, Institute of Kidney Disease Research, Yonsei University, Korea*
PGN003	Time-updated systolic blood pressure and progression of chronic kidney disease in patients with glomerulonephritis	**Hyung Woo Kim** *Severance Hospital, Korea*
PGN004	Compliance and adherence to drug treatments on patients with chronic kidney disease (CKD) in high prevalence areas of North Central Province, srilanka	**Harith Manathunga** *Kotelawala defence university, Sri Lanka*
PGN005	Effect of graphene-based nanomaterials treatment in kidney fibrosis	**Lilin Li** *SMG-SNU Boramae Medical Center, Korea*
PGN006	Galactose-deficient IgA1 as a biomarker of IgA nephropathy	**Jin Sug Kim** *Kyung Hee University School of Medicine, Korea*
PGN007	Clinical implication of isolated sub-nephrotic proteinuria and role of renal biopsy	**Hyoungnae Kim** *Soonchunhyang University Seoul Hospital, Korea*
PGN008	Time-trends in characteristics and prognosis of IgA nephropathy in Korea	**Sehoon Park** *Seoul National University Hospital, Korea*
PGN009	Clinical characteristics and outcomes in patients with autosomal dominant polycystic kidney disease on renal replacement therapy	**Jin Hyuk Paek** *Keimyung University Dongsan Medical Center, Korea*
PGN011	Statin may reduce adverse renal outcome in CKD patients: Result from KNOW-CKD study	**Gongmyung LEE** *Severance Hospital, Korea*
PGN012	Epidemiologic changes of glomerular disease over time in South Korea	**Minjung Kang** *Seoul National University Hospital, Korea*
PGN013	Urinary Molybdenum Levels and Chronic Kidney Disease: National Health and Nutrition Examination Survey (1999–2016)	**Jeonghwan Lee** *SMG-SNU Boramae Medical Center, Korea*
PGN014	Agonistic cMet Antibody Prevents Kidney Fibrosis in Acute Kidney Disease Mice Model	**Jeonghwan Lee** *SMG-SNU Boramae Medical Center, Korea*
PGN015	Altered renal lipid metabolism by aging	**Sang Ho Lee** *Kyung Hee University Hospital at Gangdong, Korea*
PGN016	Urinary cytokines as non-invasive biomarkers of IgA nephropathy.	**Jin Sug Kim** *Kyung Hee University Medical Center, Korea*
PGN017	Significant urinary metabolites in the progression of chronic kidney disease	**Yaerim Kim** *Keimyung University Dongsan Medical Center, Korea*
PGN018	What is the best predictable subfraction for cardiovascular outcomes in patient with chronic kidney disease?	**Yaerim Kim** *Keimyung University Dongsan Medical Center, Korea*
PGN019	Renal and patient outcomes of glomerular disease in Korea	**Minjung Kang** *Seoul National University Hospital, Korea*
PGN020	Therapeutic Potential of Natural Compound 2, 3, 5, 4′-tetrahydroxystilbene-2-O-β-D glucoside in Focal Segmental Glomerulosclerosis	**Uyanga Bayarsengee** *Khan-Uul secondary hospital, Mongolia*
PGN021	Granulomatosis with polyangiitis presenting as cholangitis and acute kidney injury	**Jong Hwan Jung** *Wonkwang University School of Medicine, Korea*
PGN022	Atypical renal pathologic findings in anti-neutrophil cytoplasmic antibody associated vasculitis	**Jung Gu Na** *Gyeongsang National University Changwon Hospital, Korea*
PGN023	A mechanism of lyso-Gb3-induced podocyte injury	**Soyoung Kim** *Soonchunhyang University Cheonan Hospital, Korea*

Poster Presentation list

PGN024	Immunoglobulin A nephropathy with superimposed podocytopathy	Hee Rim Kang *Wonkwang University School of Medicine, Korea*
PGN025	Successful treatment of RPGN due to ANCA associated pauci-immune crescentic glomerulonephritis	Dayoung Kang *Chosun University Hospital, Korea*
PGN026	Membranoproliferative glomerulonephritis with abnormaly large IgA deposits in cryptogenic liver cirrhosis	Jong Hwan Jung *Wonkwang University Hospital, Korea*
PGN027	Src kinases inhibition prevents the development of renal tubulointerstitial fibrosis	Debra Dorotea *Ewha Womans University, Korea*
PGN028	Identification of potential chemical risk factors for renal function among Korean women	Habyeong Kang *Seoul National University, Korea*

May 25 (Sat)

Glomerular and Tubulointerstitial Disorders (CKD) — Exhibition Hall, 3F

PGN029	Multiple arterial thrombosis in nephrotic syndrome	Soo Ryeong Ryoo *Ajou University Hospital, Korea*
PGN030	A case of tubulointerstitial nephritis in a patient with an influenza A infection	Hee Hyang Moon *The Catholic University of Korea, Bucheon St. Mary's Hospital, Korea*
PGN031	Cigarette smoke exacerbates kidney injury in diabetic rats	Songling Jiang *Ewha Womans University, Korea*
PGN032	Deep Neural Network for Estimating Glomerular Filtration Rate	Mun Hee Chai *Wonju Severance Christian Hospital, Korea*
PGN033	Body shape change in relation to incident chronic kidney disease in Korean adults	Jin Jae Jeong *Wonju Severance Christian Hospital, Korea*
PGN034	A case of multi-organ involvement in IgG4-related disease with superimposed IgA nephropathy	JI Wook Choi *Chungbuk National University Hospital, Korea*
PGN035	Clinical significance of C4d deposition in pediatric HSP nephritis	Heamin Jang *Kyungpook National University Hospital, Korea*
PGN036	Focal segmental glomerulosclerosis and granulomatous interstitial nephritis caused by bisphosphonate	Jong Hwan Jung *Wonkwang University Hospital, Korea*
PGN037	Effects of topiroxostat on renal fibrosis in chronic renal failure with hypercholesterolemia.	You-Jin Kim *Kyungpook National University Hospital, Korea*

PGN038	A novel PAX2 mutation c.130C>G (L44V) identified by exome sequencing in a family with end-stage renal disease in adulthood	Taehee Kim *Inje University Busan Paik Hospital, Korea*
PGN039	Administration of 2-mercaptoethanol prevents oxidative stress and inflammation during unilateral ureteral obstruction	Daeun Moon *Jeju National University, Korea*
PGN040	The association between blood heavy metals and chronic kidney function among Korean healthy women: Impact of (pre) hypertension	Gowoon Lee *Seoul National University, Korea*
PGN041	Renal hemosiderosis secondary to intravascular hemolysis after mitral valve repair	In Hee Lee *Daegu Catholic University School of Medicine, Korea*
PGN042	THE EFFECT OF RAAS BLOKERS THROUGH BIOMARKERS IN IGA NEPHROPATHY	Myungjun Seong *Inje University Haeundae Paik Hospital, Korea*
PGN043	ANCA associated vasculitides in a patient with positive serologic test for Hantan virus	Kyung Pyo Kang *Chonbuk National University Medical School, Korea*
PGN044	Role of calcitriol on Wnt 5a expression in osteoblast	Kuo-Cheng Lu *Fu Jen Catholic University, Taiwan*
PGN045	Severe IgA nephropathy who showed normal urinalysis and no hypertension.	Hyaejin Yun *Dr.Cho's kidney center, Korea*
PGN046	Renal biopsy & pathology together at OPD level without admission	Byoung-soo Cho *Dr.Cho's kidney center, Korea*
PGN047	C1q nephropathy and membranous nephropathy in a sibling at the same time.	Sung-min Jung *Dr.Cho's kidney center, Korea*
PGN048	c-ANCA positive pauci-immune crescentic glomerulonephritis in a patient with Henoch–Schönlein purpura (HSP)	Yoonmi Choi *Inje University Sanggye Paik Hospital, Korea*
PGN049	Urine hydroxyproline as a marker of renal dysfunction in patients with chronic kidney disease	Jongho Son *The Catholic University of Korea, Yeouido St. Mary's Hospital, Korea*
PGN050	Urinary angiotensinogen to creatinine ration (UAGT/Cr) is not a predictive biomarker for renal progression in autosomal dominant polycystic kidney disease: KNOW-CKD study	Hayne Cho Park *Kangnam Sacred Heart Hospital, Korea*
PGN051	Recurrent cyst infection in patients with autosomal dominant polycystic kidney disease	Jin Hyuk Paek *Keimyung University Dongsan Medical Center, Korea*
PGN052	Prevalence of Chronic Kidney Disease Among HIV-infected Population in Asia: A Systematic Literature Review and Meta-Analysis	Mohammad Adil *School of Pharmaceutical Education and Research, Jamia Hamdard, India*

Poster Presentation list

Poster Presentation list

PGN053	Remodelin attenuates renal interstitial fibrosis via modulation of epithelial-to-mesenchymal transition	Eun Sil Koh *The Catholic University of Korea Yeouido St. Mary's Hospital, Korea*
PGN054	Phosphatidylinositol-3 kinase (PI3-kinase) has a protective role at the early stage of angiotensin II-induced podocyte injury by inducing autophagy	Tae-Sun Ha *Chungbuk National University College of Medicine, Korea*
PGN055	Nephrotic Syndrome in Post Hematopoietic Stem Cell Transplantation Patients – 20 Years' Experience in a Single Center	Myungah Ha *The Catholic University of Korea, Bucheon St. Mary's Hospital, Korea*
PGN056	Effect of Febuxostat on Renal Outcomes in Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials	Md Azharuddin *School of Pharmaceutical Education and Research, Jamia Hamdard, India*
PGN057	Cystatin C: Significance in Cardiovascular Disease among Indian population.	Asgar Ali *All India Institute of Medical Sciences Patna, India*

May 24 (Fri)

Hypertension and Vascular Biology — Exhibition Hall, 3F

PHV001	The influence of blood pressure patterns on renal outcomes in patients with chronic kidney disease: the long-term follow up result of the APrODiTe-2 study	Ran-hui Cha *National Medical Center, Korea*
PHV002	The Association between Longitudinal Blood Pressure Trajectory and Progression of Chronic Kidney Disease: Results from KNOW-CKD	Young Su Joo *Severance Hospital, Korea*
PHV003	Fluid Status as a Determinant for Pulse Pressure and Endothelial Function in Peritoneal Dialysis Patients	Yeunmi Kang *Ewha Womans University Mokdong Hospital, Korea*
PHV004	Effect of ambulatory blood pressure monitoring on renal outcome in patients with chronic kidney disease: prospective randomized comparative study	Yunmi Kim *Inje University Busan Paik Hospital, Korea*
PHV005	ROLE OF FAMILY TO HYPERTENSION PATIENTS IN IMPROVING LIFE QUALITY: A Literature Study	Dewayan Ekowanti *Universitas Gadjah Mada, Indonesia*
PHV006	The effects of blood pressure components on cardiovascular events in a korean hypertensive population according to age and sex: A nationwide population-based cohort study	Eungyu Kang *Ewha Womans University Mokdong Hospital, Korea*
PHV007	The impact of the blood pressure classification on the cardiovascular events among the individuals without any antihypertensive medication; A nationwide population-based cohort study	Hyoungnae Kim *Soonchunhyang University Seoul Hospital, Korea*
PHV008	LOW GLOMERULAR FILTRATION RATE IS ASSOCIATED WITH HEMORRHAGIC TRANSFORMATION IN ACUTE ISCHEMIC STROKE PATIENTS: A META-ANALYSIS	Gaurav Nepal *Tribhuvan University Institute of Medicine, Nepal*
PHV009	Acute renal infarction with ascending aortic thrombosis in patient presenting with abdominal pain and upper extremity numbness: a case report	Jun Hyung Cho *Gyeongsang National University Changwon Hospital, Korea*
PHV010	Renovascular Hypertension in a Girl with Williams-Beuren Syndrome	Se Jin Park *Geoje Children's Hospital, Korea*

May 25 (Sat)

Hypertension and Vascular Biology — Exhibition Hall, 5F

PHV011	Factors related to TC-HDL and LDL-HDL Ratio in Hypertensive Patient	Ainun Nisa *Faculty of Medicine, Universitas Gadjah Mada, Indonesia*
PHV012	Histone deacetylase inhibitor CG200745 ameliorates high fat diet-induced hypertension via inhibition of vascular smooth muscle contraction	Ga Eun Yoon *Keimyung University School of Medicine, Korea*
PHV013	Low skeletal muscle mass predicts incident hypertension in Korean men: A prospective cohort study	Ji Min Han *Kangbuk Samsung Hospital, Korea*
PHV014	Predictive value of pulse wave velocity on the risk of end-stage renal disease	Jin Seon Jeong *Seoul National University Hospital, Korea*
PHV015	Furosemide Loaded Self Nano Emulsifying Drug Delivery System Enhanced Diuresis and Natriuresis in Rats	Pankajkumar Yadav *SHUATS, India*
PHV016	A case of Idiopathic systemic capillary leak syndrome (ISCLS) in a toddler	Nodira Murtalibova *Pusan National University Hospital, Korea*
PHV017	Serum calcium level has a differential effect on the progression of coronary artery calcification depending on renal function, but not phosphorus or calcium × phosphorus product.	Moon Hyoung Lee *Yonsei University College of Medicine, Korea*
PHV018	Assessing Malnutrition Risk using Nutrition Risk Screening 2002 and Malnutrition Universal Screening Tool and the Correlation toward Nutritional Status and Dietary Intake in Hypertensive and Cardiovascular Patients	Farah Faza *Universitas Gadjah Mada, Indonesia*
PHV019	Serum gamma glutamyl transferase activity among hypertensive patients	Saroj Kunwar *Modern Technical College, Nepal*

Poster Presentation list

May 24 (Fri)

Transplantation — Exhibition Hall, 3F

PTR001	HIGH DOSE CNIs IN DESENSITIZATION OF CROSS MATCH POSITIVE RENAL TRANSPLANT RECIEPIENTS	ROHIT RUNGTA *MEDICA SUPERSPECIALITY HOSPITAL, India*
PTR002	Impact of 1-year Post-transplant Tacrolimus Trough Levels on Long-term Renal and Cardiovascular Outcomes in Kidney Transplant Recipients	Hee-Yeon Jung *Kyungpook National University Hospital, Korea*
PTR003	Predictors of progressive chronic kidney disease in liver transplant recipients: Analyses of a 10-year follow-up cohort	Kyungho Lee *Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*
PTR004	Impact of peri-transplant red blood cell transfusion on post-kidney transplant graft failure	Kyungho Lee *Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*
PTR005	Effect of severe diarrhea on kidney transplant outcomes	Ji Eun Kim *Seoul National University Hospital, Korea*
PTR006	Risk of graft failure in the kidney transplant recipients with cured post-transplant cancer	Ji Eun Kim *Seoul National University Hospital, Korea*
PTR007	Prophylaxis and Outcomes of Pneumocystis jiroveci Pneumonia in Renal Transplant Recipients in Korea	Tai Yeon Koo *Seoul National University Hospital, Korea*
PTR008	Evaluation for the risk factors of donors affecting graft function in case of deceased donor renal transplantation in Korea	Jin Ho Lee *Bong Seng Hospital, Korea*
PTR009	Incident depression of kidney transplant recipients in South Korea: a long-term population-based study	Yong Chul Kim *Seoul National University Hospital, Korea*
PTR010	Time-trends in kidney transplantation in South Korea; a nationwide cohort study from 2007 to 2015	Sehoon Park *Seoul National University Hospital, Korea*
PTR011	Incident Dementia in Kidney Transplantation Recipients: A Nationwide Population-Based Cohort Study in Korea	Seon Ha Baek *Hallym University Dongtan Sacred Heart Hospital, Korea*
PTR012	Incident Parkinson Disease in Kidney Transplantation Recipients: A Nationwide Population-Based Cohort Study in Korea	Seon Ha Baek *Hallym University Dongtan Sacred Heart Hospital, Korea*
PTR013	Long-term Post-transplant Clinical Outcomes in Deceased Donor Kidney Transplantation: Report from a Single-center experience for 20 Years	Woo-yeong Park *Keimyung University School of Medicine, Keimyung University Kidney Institute, Korea*
PTR014	Impact of Acute Kidney Injury in Deceased Donors with High Kidney Donor Profile Index on Post-Transplant Clinical Outcomes: Multicenter Cohort Study	Woo-yeong Park *Keimyung University School of Medicine, Keimyung University Kidney Institute, Korea*
PTR015	Glaucoma incidence in kidney transplant recipients in South Korea: a long-term population-based study.	Yong Chul Kim *Seoul National University Hospital, Korea*
PTR016	Gut microbiota may affect a variability of tacrolimus trough levels in kidney transplant recipients	Ji Eun Kim *Seoul National University Hospital, Korea*
PTR017	Cardiovascular disease after kidney transplantation: A Nationwide population-based cohort study	Ji Eun Kim *Seoul National University Hospital, Korea*
PTR018	Residence and kidney transplantation outcomes in South Korea: A Nationwide population-based cohort study	Ji Eun Kim *Seoul National University Hospital, Korea*
PTR019	Clinical Outcomes of Kidney Transplant Recipients with Positive Luminex and Negative Crossmatch	Tae Hyun Ban *School of Medicine, The Catholic University of Korea, Korea*
PTR020	Long-term outcomes of elderly living donors: a nationwide population-based study	Hye Eun Yoon *The Catholic University of Korea, Incheon St. Mary's Hospital, Korea*
PTR021	Effect of Bortezomib on Chronic Antibody Mediated Rejection in Kidney Transplantation Recipients	Hyung Duk Kim *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*
PTR022	Impact of Isoagglutinin Titer Rebound in ABO Incompatible Kidney Transplantation	Hyung Duk Kim *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*
PTR023	Impact of Dermoscopy : A non invasive useful tool for organ transplant patients in developing country	Shambhu Joshi *Far western community Hospital, Nepal*
PTR024	Impact of Donor and Recipients Factors on Patient and Graft Survival among Recipients of Deceased Kidney Transplants at KAMC	Abdulla Al-Sayyari *King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia*
PTR025	The Influence of Cytomegalovirus Infection in Kidney Transplant Recipients with Pneumocystis jirovecii pneumonia	SUA LEE *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*

Poster Presentation list

May 25 (Sat)

Transplantation — Exhibition Hall, 3F

PTR026	CENTRAL DIABETES INSIPIDUS UNMASKED AFTER KIDNEY TRANSPLANT: A CASE REPORT	**Sherida Edding** *St. Luke's Medical Center - Global City, Philippines*
PTR027	Risk factors of hypercalcemia after kidney transplantation	**Han Ro** *Gachon University Gil Medical Center, Korea*
PTR029	High HLA DQ Epitope-Mismatch loads and tacrolimus lowest level < 6ng/ml in the past 6month are associated with development of de novo DSA	**Dong Ryeol Lee** *Maryknoll Medical Center, Korea*
PTR030	Malignancy in Children with Kidney Transplantation: A single-center experience	**Jiwon Jung** *Asan medical center, Korea*
PTR031	Clinical Implication of Duration of Graft Function Recovery after Kidney Transplantation	**Jeong Ho Kim** *The Catholic University of Korea, Daejeon St. Mary's Hospital, Korea*
PTR032	Efficacy and Safety according to dose of Valganciclovir for Cytomegalovirus (CMV) Prophylaxis in Transplantation: network Meta-analysis using recent data.	**Seon Deok Hwang** *Inha University Hospital, Korea*
PTR033	Why did we do an indication biopsy in early period after kidney transplantation?	**Jin Hyuk Paek** *Keimyung University Dongsan Medical Center, Korea*
PTR034	Perirenal abscess at the site of focal necrosis in patient with renal transplant	**Young Rok Ham** *Chungnam National University Hospital, Korea*
PTR035	Impact of periodontitis on recipient outcomes after kidney transplantation	**Hyeonjin Min** *Korea University Anam Hospital, Korea*
PTR036	Pre-transplant Osteoporosis and Osteopenia are Risk Factors for Fractures after Kidney Transplantation	**Jeong-Hoon Lim** *Kyungpook National University Hospital, Korea*
PTR037	Impact of Conversion from Cyclosporine to Tacrolimus on Glucose Metabolism and Cardiovascular Risk Profiles in Long-Term Stable Kidney Transplant Recipients	**Jeong-Hoon Lim** *Kyungpook National University Hospital, Korea*
PTR038	Acute femoral neuropathy following kidney transplantation: a case report	**A Young KIm** *Yeungnam University Medical Center, Korea*
PTR039	A case of Urinary stone after kidney transplantation	**Soo Hyun Han** *Chungnam National University Hospital, Korea*
PTR040	The graft and patient survival of kidney transplantation according to ethnicity in US Kidney Transplant Recipients	**Sunmin Kim** *Kosin University Gospel Hospital, Korea*
PTR041	Case report: A case of ABO incompatible kidney transplantation with very high-titer anti-ABO antibody along with positive B-CDC crossmatch	**Kitae Kim** *Hanseo Hospital, Korea*
PTR042	Survey of BK screening and management protocols in comparison to published consensus guidelines in Yeongnam area of South Korea	**Ye Na Kim** *Kosin University Gospel Hospital, Korea*
PTR043	CMV retinitis after kidney transplantation	**Haetbit Hawng** *Chungnam National University Hospital, Korea*
PTR044	Incident cancer after kidney transplantation in South Korea: a nationwide-population based study	**Mi-Yeon Yu** *Hanyang University Guri Hospital, Korea*
PTR045	Safety and efficacy of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitor in kidney transplant recipients	**Hyukyong Kwon** *Hanseo Hospital, Korea*
PTR046	A Case Study : Nutritional Care for Kidney Transplantation Patients with Malnutrition in Cipto Mangunkusumo General Hospital, Jakarta	**Zahrina Tresna Wahidin** *Hospital, Indonesia*
PTR047	Gut microbiome and acute rejection after kidney transplantation	**Hyunjeong Cho** *Chungbuk National University Hospital, Korea*
PTR048	Dual induction with anti-thymocyte globulin and rituximab in sensitized kidney transplant patients.	**Kitae Kim** *Hanseo Hospital, Korea*
PTR049	Clinical significance of CD8+ T cell subset analysis for the prediction of acute allograft rejection in kidney transplant recipients	**Kyoung-Woon Kim** *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*

May 24 (Fri)

Non-dialysis CKD — Exhibition Hall, 5F

PNC001	Apolipoprotein B predicts the risk of end-stage renal disease	**Soie Kwon** *Seoul National University Hospital, Korea*
PNC002	Expert-level segmentation using deep learning for the volumetry of polycystic kidney and liver	**Hyunsuk Kim** *Chuncheon Sacred Heart Hospital, Korea*
PNC003	Effect of chronic renal failure on emotion and depression	**Hyo-Wook Gil** *Soonchunhyang University Cheonan Hospital, Korea*
PNC004	Allergic rhinitis is closely correlated with impaired kidney function: A nationwide cross sectional study	**Sangmi Lee** *Severance Hospital, Korea*
PNC005	Evaluation of predictive performance of mineral and bone disorder markers for adverse outcomes in patients with chronic kidney disease	**Geun Woo Ryu** *Severance Hospital, Korea*

Poster Presentation list

PNC006	Bone mineral density discordances between lumbar spine and femur in patients with chronic kidney disease	**Keunyoung Kim** *Pusan National University Hospital, Korea*
PNC007	The Association between Income Disparities and Risk of Chronic Kidney Disease: A Nationwide Cohort Study of Seven Million Adults in Korea	**Jee Young Lee** *Severance Hospital, Korea*
PNC008	Sex Disparities and Risk of Chronic Kidney Disease: A Nationwide Cohort Study of Seven Million Adults in Korea	**Shinchan Kang** *Severance Hospital, Korea*
PNC009	Dairy Intake and Incident Chronic Kidney Disease in Hypertensive Patients: A Community-Based Prospective Cohort Study	**Jong Hyun Jhee** *Inha University Hospital, Korea*
PNC010	Decrease in waist-to-hip ratio significantly reduced the risk of incident chronic kidney disease even in non-obese non-alcoholic fatty liver disease	**Mi Jung Lee** *Bundang CHA Medical Center, Korea*
PNC011	Anemia, iron status, and anemia development in relation to body mass index in non-dialysis chronic kidney disease patients: The results from the KNOW-CKD study	**Hyo Jin Kim** *Dongguk University College of Medicine, Korea*
PNC012	High-sensitive C-reactive protein and all-cause mortality in Korean patients with chronic kidney disease: Results from KNOW-CKD	**Keun Hyung Park** *Severance Hospital, Korea*
PNC013	Effect of Dietary Salt intake on Renal outcomes in Advanced CKD patients from KNOW-CKD study	**Minjung Kang** *Seoul National University Hospital, Korea*
PNC014	The effect of serum corrected calcium and other kidney-related factors on left ventricular hypertrophy in pre-dialysis chronic kidney disease	**Miyeun Han** *Pusan National University Hospital, Korea*
PNC015	Risk factors of arterial stiffness in chronic kidney disease depending on diabetes mellitus: Data analysis from the KoreaN Cohort Study for Outcomes in Patients with Chronic Kidney Disease (KNOW-CKD)	**Yunmi Kim** *Inje University Busan Paik Hospital, Korea*
PNC016	Urine Chloride level and Progression of Chronic Kidney Disease	**Jinseok Kim** *Severance Hospital, Korea*

May 25 (Sat)

Non-dialysis CKD — Exhibition Hall, 5F

PNC017	Association of the Trajectories of Metabolic Component and Outcomes in Patients with Chronic Kidney Disease	**Kyung Don Yoo** *Ulsan University Hospital, Korea*
PNC018	Effects of Case Management Program for Patients Type 2 Diabetes Mellitus with Chronic Kidney Disease Stage 3 in Wangwiset Hospital, Trang Province, Thailand	**Kasetsak Luanseng** *Ministry of Public Health, Thailand*
PNC020	The Prevalence, Awareness and Treatment of Chronic Kidney Disease in Korean Adults	**Seung Goo Baek** *Eulji University Hospital, Korea*
PNC021	The characteristics of dietary intake according to chronic kidney disease stage in Korea: the Korean National Health and Nutritional Examination Survey	**Seon Mi Kim** *Ewha Womans University Medical Center, Korea*
PNC022	Muscle Mass, Physical Activity and Chronic Kidney Disease in Older Adults	**Soo Jeong Choi** *Soonchunhyang University Bucheon Hospital, Korea*
PNC023	Clinical significance of creatinine variability and its impact on cardiovascular outcomes in general population	**Soojin Lee** *Seoul National University Hospital, Korea*
PNC024	The association between plasma neutrophil gelatinase-associated lipocalin and non-albumin proteinuria in patients with chronic kidney disease	**Byung Min Ye** *Pusan National University Yangsan Hospital, Korea*
PNC025	Regulation of hepcidin levels by vitamin D and omega-3 fatty acid in 5/6 nephrectomy rat model	**Su Mi Lee** *Dong-A University, College of Medicine, Korea*
PNC026	Insulin-like growth factor binding protein 3 specific DNA aptamer attenuated renal tubular fibrosis	**Mi Jung Lee** *Bundang CHA Medical Center, Korea*
PNC027	Vitamin D deficiency accentuate anti-proteinuria effect of calcitriol in Patients with Chronic Kidney Disease: A Randomized Controlled Trial	**Min-Tser Liao** *Taoyuan Armed Forces General Hospital, Taiwan*
PNC028	The effect of increased blood microRNA on autophagy dysregulation in cardiac cells and cardiac complications in chronic kidney disease	**Kyoung Hye Kong** *Ewha Womans University School of Medicine, Korea*
PNC029	Concomitant Acute Pyelonephritis, Acute Kidney Injury, and Obstruction Duration Affects Renal Outcome in Obstructive Uropathy by Urolithiasis	**Jin Ho Hwang** *Chung-Ang University Hospital, Korea*
PNC030	The relationship between plasma blood viscosity and renal function in patients with coronary artery disease	**Yun Jung Oh** *Cheju Halla General Hospital, Korea*
PNC031	The impact of abdominal aortic calcification on progression of chronic kidney disease	**So Mi Kim** *Dankook University Hospital, Korea*

May 24 (Fri)

Others — Exhibition Hall, 3F

POT001	Functional compartmental RNA-seq analysis of the kidney according to aging	**Ju-Young Moon** *Kyung Hee University Hospital at Gangdong, Korea*
POT002	Initial renal manifestations and risk factors affecting renal function in patients with ankylosing spondylitis	**Minah Kim** *Chonnam National University Hospital, Korea*

Poster Presentation list

POT003	Non-alcoholic fatty liver disease and abdominal obesity are associated with coronary calcification in mild renal insufficiency	**Seok-hyung Kim** *Gangnam Severance Hospital, Korea*
POT004	Vascular Catheter-Site Care Using Different Skin Antiseptics for Prevention of Catheter-Related Blood Stream Infection: A Meta-Analysis	**Martin Ogbac** *Ospital ng Makati, Philippines*
POT005	Case of 23-year-old woman who are undergoing hemodialysis with leg mass.	**Won Jung Choi** *Chungnam National University Hospital, Korea*
POT006	Complementtary and Alternative Medicine (CM)Deterioration of Chronic Kidney Patients in .Nepal	**Hari Prasad Dulal** *ASUNTA Medicare Hospital pvt ltd, Nepal*
POT007	Preclinical and clinical study in Alcohol Dependence Syndrome patients with Lipid profile and cardiac markers to correlate occurrence of cardiovascular disease	**Hari Prasad Dulal** *ASUNTA Medicare Hospital pvt ltd, Nepal*
POT008	Case Report Cardiovascular disease and Acute Kidney Disease caused by Cardiopulmonary Resuscitation in blood sugar .	**Hari Dulal** *ASUNTA Medicare Hospital pvt ltd, Nepal*
POT009	DETECTION OF DIURETICS IN HUMAN URINE: KEY REGULATORS OF EXTRACELLULAR FLUID & KIDNEY DISORDERS	**Awanish Upadhyay** *NATIONAL DOPE TESTING LABORATORY, India*
POT010	Investigation of an Ayurvedic formulation comprising Arjuna bark and Gau-mutra on cardiomyopathy and nephropathy in experimental model	**TEJASKUMAR SHARMA** *Saurashtra University, India*
POT011	Modifiable factors associated with health-related quality of life in patients with diabetic kidney disease	**Suhyun Kim** *Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*
POT012	Prevalence and risk factors of baclofen neurotoxicity in patients with severe chronic kidney disease	**Minseon Cheong** *Asan Medical Center, University of Ulsan College of Medicine, Korea*
POT013	Long-term particulate matter exposure increases the mortality risk of patients with end-stage renal disease	**Jiyun Jung** *Seoul National University School of Public health, Korea*
POT014	The presence of simple renal cyst is associated with increased risk of albuminuria in young adults	**Hyo Jin Boo** *Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea*
POT015	EFFECT OF EXERCISE INTERVENTION ON STRENGTH OF MUSCLES AND LEVEL OF FATIGUE IN PATIENTS UNDERGOING DIALYSIS IN A TERTIARY HOSPITALIN MYSORE" - PILOT STUDY	**PRASHANTH V MANGALVEDHE** *RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES, India*
POT016	A Case Report of Gramoxone inteon intoxication	**Houn Jung** *Chuncheon Sacred Heart Hospital, Korea*
POT017	Effect of Herbal Medicines on Kidney Function Markers in Type II Diabetic Subjects	**Senthil Kumar Subramani** *Jiwaji University, India*
POT018	Renal outcome in patients with horseshoe kidney	**Minjung Kang** *Seoul National University Hospital, Korea*
POT020	CUSTOM-MADE DOPPLER ULTRASOUND FLOW SIMULATOR FOR DIALYSIS ACCESS USING CONTINUOUS RENAL REPLACEMENT THERAPY MACHINE	**Cheolsu Kim** *Hallym University Sacred Heart Hospital, Korea*
POT021	Utilization of Combine Genetic Algorithm and Fuzzy K-Nearest Neighbor (GAFKNN) as an Early Detection of Kidney Disease	**Rifaldy Fajar** *Yogyakarta State University, Indonesia*

May 25 (Sat)

Others — Exhibition Hall, 3F

POT022	Renal outcomes of large volume paracentesis in cirrhotic patients with spontaneous bacterial peritonitis, a nephrologist's perspective.	**Rabeea Azmat** *Aga Khan Universty Hospital, Pakistan*
POT023	Studies on the effect of vitamin C on crystallization and crystal growth inhibition and dissolution of struvite crystals – an in vitro study	**Surya Ram Duwal** *Yenepoya University, Nepal*
POT024	PLANT EXTRACTS AS CALCIUM SOLUTIONS IN KIDNEY STONE	**Indra Suardi** *University of Hasanuddin Makassar, Indonesia*
POT025	GOLD-X Case Series: Increment of Physical Activity and Home Exercises as Therapy on Elderly with Chronic Kidney Disease, Hypertension, Diabetes, Obesity and More	**Alvin Wiharja** *Svarga Rehab and Sports, Indonesia*
POT026	Attitudes toward advance care plan and hemodialysis as a life-sustaining therapy in hemodialysis patients	**Jangwook Lee** *Seoul National University Hospital, Korea*
POT027	SOCIO-DEMOGRAPHIC FACTORS, DIETARY INTAKE AND NUTRITIONAL STATUS IN HEMODIALYSIS PATIENTS IN UNIVERSITAS GADJAH MADA HOSPITAL YOGYAKARTA-INDONESIA	**Farah Faza** *Universitas Gadjah Mada, Indonesia*
POT028	Impact of Energy and Protein Intake on Hand Grip Strength, and Nutritional Status in Maintenance Hemodialysis Patients	**Lisa Rosyida** *UGM Hospital, Indonesia*
POT029	Association between Hemodialysis Vintage and Weight Loss in Maintenance Hemodialysis Patients in Universitas Gadjah Mada Hospital Yogyakarta-Indonesia	**Okta Haksaica Sulistyo** *UGM Hospital, Indonesia*
POT030	Dietary Intake Survey of Maintenance Hemodialysis Patients in Universitas Gadjah Mada Hospital, Yogyakarta-Indonesia	**Yusmiyati Yusmiyati** *UGM Hospital, Indonesia*

Poster Presentation list

POT031	Determining Energy And Protein Intake On Day With And Without Hemodialysis In Indonesia Tertiary Level Hemodialysis Unit	**Luthfianti Diana** *Cipto Mangunkusumo General Hospital, Indonesia*
POT032	Micronutrients Adequacy Intake In Hemodialysis Patiens	**Diah Nurhayati** *Cipto Mangunkusumo Hospital, Indonesia*
POT033	Comparison between SGA (Subjective Global Assessment) and MIS (Malnutrition Inflammation Score) in Chronic Kidney Disease on Haemodialysis at Cipto Mangunkusumo General Hospital 2018	**Khaerani Angelia** *Cipto Mangunkusumo General Hospital Jakarta Indonesia, Indonesia*
POT034	ENERGY INTAKE, BODY MASS INDEX AND BODY COMPOSITION IN CHRONIC KIDNEY DISEASES ON DIALYSIS	**Quthrotur Rodliyah** *Cipto Mangunkusumo General Hospital, Indonesia*
POT035	Obesity, inflammation, and renal cell carcinoma	**Junyong Lee** *Korea University Anam Hospital, Korea*
POT036	The therapeutic efficacy of water soluble coenzyme Q10 in experimental model of tacrolimus induced diabetes mellitus.	**YI QUAN** *The Catholic University of Korea, Seoul St. Mary's Hospital, Korea*
POT037	KIDNEY FAILURE AS INITIAL PRESENTATION OF TUBEROUS SCLEROSIS IN A 42-YEAR OLD FILIPINO	**Ray Alexandra Consuelo Salazar** *Rizal Medical Center, Philippines*
POT038	Scintigraphic Evaluation of Renoprotective Effects of Coenzyme Q10 in a Rat Renal Ischemia-Reperfusion Injury	**Aylin AKBULUT** *Ankara Training and Application Hospital, University of Health Sciences, Turkey*
POT039	Case Study: Impact of Social Support on Coping Strategies for Patients with Chronic Kidney Diseases on Dialysis	**Debby Nursita Dewi** *KPCDI Tangerang Raya, Indonesia*
POT040	Amelioration of N-diethylnitrosamine (DEN) and ferric nitrilotriacetate (FE-NTA) induced renal cell carcinoma by Carissa carandas embedded silver nanoparticles in animal model via down regulating oxidative stress and inflammatory markers	**Deepika Singh** *SHUATS, Allahabad, India*
POT041	Protective effect of biofabricated Prosopis cineraria silver nanoparticles against renal carcinoma via knock down oxidative stress and inflammation by regulating NF-κB pathway	**Ekta Yadav** *SHUATS, India*
POT042	Adherence to the Exercise Program in Patients with Chronic Kidney Disease Undergoing Hemodialysis at Tertiary Hospital	**VIJAY SAMUEL RAJ V** *JSS COLLEGE OF PHYSIOTHERAPY, India*
POT043	A case–control study on environmental and biological risk factors for renal calculi persisting in a coastal Union Territory, India	**Prakash Mathiyalagen** *Indira Gandhi Medical College & Research Institute, Puducherry, India*
POT044	Two Cases of ACEi/ARB fetopathy	**Jakhongir Tojiboev** *National children's hospital, Uzbekistan*

Exhibition

3F



Exhibitors

Lobby, 3F

- S1 HANDOK
- S2 YUHAN
- S3 SK Chemicals
- S4 Fresenius Medical Care Korea
- S5 Baxter
- S6 Boryung

Exhibitors

Exhibition Hall, 3F

- E1 & E2 Sanofi Genzyme
- E3 AbbVie Korea
- E4 Servier Korea
- E5 & E6 SANOFI-AVENTIS KOREA
- E7 & E8 Asahi Kasei Medical Trading(Korea)
- E9 LG Chem
- E10 Astellas Pharma Korea
- E11 Medtronic Korea
- E12 NIPRO DONGDUK MEDICAL

Exhibition

5F



Exhibitors

Lobby, 5F

S7	Korea Otsuka Pharmaceutical
S8	JW Pharmaceutical
S9	CJ HealthCare
S10	Kyowa Hakko Kirin Korea
S11	Roche Korea

Promotional Desks

Exhibition Hall, 5F

P1	Korea National Institute for Bioethics Policy
P2	Seoul National University Biomedical Informatics (SNUBI) Blockchain based integrated medical informatics services platform, HealthAvatar
P3	Mareunnaero

Exhibitors

Exhibition Hall, 5F

E13	Bayer Korea
E14	ChongKunDang Pharm
E15	BARD KOREA
E16	Myoung Poom Medical
E17	B. Braun Korea
E18 & E19	MSD Korea
E20 & E21	Alvogen korea
E22 & E23	Takeda Pharmaceuticals Korea
E24	Pfizer Korea
E25	LDS pharm
E26 & E27	Daewon Pharm
E28	HAJOO Corp
E29	SAMJIN PHARM
E30	Hanmi Phamaceutical
E31	Daiichi Sankyo Korea

Sponsors

Platinum Sponsors

FRESENIUS MEDICAL CARE
Baxter
YUHAN

Gold Sponsors

HANDOK
Otsuka
KYOWA KIRIN
SK chemicals
JW Pharmaceutical
Roche
BORYUNG
CJ HealthCare

Silver Sponsors

Daewoon 대원제약
Alvogen
Takeda
Takeda Pharmaceuticals Korea CO., LTD.
SANOFI
SANOFI GENZYME

Memo

이유있는 처방율 1위!

왜, 대한민국 많은 의사들은 카리메트를 처방 할까요?
대한민국의 대표적인 고칼륨혈증치료제- 근화카리메트는 5㎛이하의
레진 미립자 함유량을 0.1% 이하로 제조되고 있으며
최고의 안전성을 배려한 레진 제제이기 때문입니다

5㎛이하의 레진 미립자는 장내 점막을 경유하여 체내흡수가 될 수 있으며
이는 세포 침착에 의하여 전염병 및 알레르기를 일으킬 가능성이 있습니다
- Payne, J. M. et al : Nature, 188, 586, 1960 -

Kalimate®
Calcium Polystyrene Sulfonate

알보젠코리아(주) www.alvogenkorea.com 080-729-5800 (수신자부담 문의전화)

원료공급원: Kowa Kowa Company, Ltd.

제조판매원: Alvogen

edarbi
azilsartan medoxomil
40mg•80mg tablets

Reference 1. William B. White, *et al*, Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension, *Hypertension* 2011;57:413-420.

Prescribing Information 【 **제품명** 】 이달비정40밀리그램(아질사르탄 메독소밀칼륨) / 이달비정80밀리그램(아질사르탄 메독소밀칼륨) 【 **유효성분** 】 아질사르탄 메독소밀칼륨 42.68mg (아질사르탄 메독소밀로서 40mg) 아질사르탄 메독소밀칼륨 85.36mg (아질사르탄 메독소밀로서 80mg) 【 **효능·효과** 】 본태성 고혈압 【 **용법·용량** 】 성인 : 이 약의 권장 초회용량은 1일 1회 40밀리그램이며, 식사와 관계없이 투여한다. 이 용량에서 혈압이 적절히 조절되지 않는 경우 1일 최대 80밀리그램까지 증량할 수 있다. 혈압강하효과는 치료시작 후 2주 이내에 나타나며, 약 4주 정도에 최대효과가 나타난다. 이 약 단독 투여로 혈압이 조절되지 않는 경우, 다른 혈압강하제(이뇨제(예: 클로르탈리돈, 히드로클로로티아지드)나 칼슘채널차단제)와 병용투여 시 추가적인 혈압강하효과가 나타날 수 있다. 【 **사용상의 주의사항** 】 1. **경고** 임신 2, 3기인 임부에 레닌-안지오텐신계(Renin-Angiotensin System, RAS)에 직접적으로 작용하는 약물 투여 시, 태아 및 신생아에게 손상 및 사망까지 유발할 수 있다. 따라서 만일 임신으로 확인될 경우 즉시 이 약의 투여를 중단해야 한다. 2. **다음 환자에는 투여하지 말 것** 1) 이 약 또는 이 약에 함유된 성분에 대하여 과민증이 있는 환자 2) 임부 3) 다음의 환자에게 이 약과 알리스키렌 제제의 병용투여: 당뇨병 환자 또는 중등증-중증의 신장애(사구체여과율<60mL/min/1.73m2) 환자 【 **저장방법** 】 차광기밀용기, 실온(1~30℃)보관, 습기를 피하여 보관 【 **수입자** 】 한국다케다제약주식회사(서울특별시 강남구 테헤란로98길8, 12층) 【 **제조자** 】 Takeda Pharmaceutical Company Ltd. (Japan)
• 이 내용은 허가사항을 요약한 것으로 자세한 정보는 제품의 첨부문서 또는 http://drug.mfds.go.kr를 확인하십시오.

DONG-A ST

Takeda 한국다케다제약주식회사

KOEDA/2017-00011E2019.M

Prograf
Tacrolimus

오랜시간 이식환자의 지킴이가 되어준 프로그랍

20

"

장기간복용에도 안전한 프로그랍은
20년동안 입증한 효능과 안정성으로
이식환자의 희망의 불을 밝힙니다.[1]

"

References
1. Kramer BK, et al. *Transpl Int.* 2016 Mar;29(3):307-14. doi: 10.1111/tri.12716. Epub 2015 Dec 11.

astellas

APRG-17-A-23

NIPRO
Your Partner in Health Care

ON-LINE HDF
NCU-18

Nipro is a world leading manufacturer of Renal products. We are committed to delivering innovative, high quality and value-added solutions to improve patient care.
This fundamental objective leads us to develop cutting-edge products that are not only safe for the medical provider, but are manufactured to alleviate the discomfort of the patient.

(주)니프로동덕메디칼 서울시 종로구 대학로 12길 4 동덕빌딩 5층 T. 02.762.3444 www.nipro.co.kr

GLIDEPATH™

Long-Term Dialysis Catheter

Exceptional Performance and Ease of Placement

Smooth Tapered Tip



바드코리아(주) 01676 서울특별시 강남구 영동대로 416 5층 (대치동, KT&G타워) T.02-2188-2900 F.02-539-3081 www.crbard.com

BD BARD has joined BD



Nifedipine 40mg Controlled release

Niferon 40

Formulation Technology
미국, 유럽 제형특허 제품입니다.

Evidence of Efficacy and Safety
스위스, 독일, 덴마크 등에서 10년 이상 처방된 제품입니다.

원료공급 및 기술제휴 Siegfried Ltd., Switzerland

제조원 에리슨제약(주)
판매원 KPP (주)경풍약품

의료전문인용

Adalat®
Long-Term Commitment to Life

Real evidence of efficacy

아달라트® 오로스는 지난 20년간 다양한 임상시험을 통해
고혈압 환자에 대한 효과와 안전성 프로파일을 입증해 왔습니다.

- INSIGHT study를 통해, 1일 1회 복용으로 24시간 일정하고 안정된 혈압조절 효과 입증[1]
- ACTION study를 통해 ,안정형 협심증을 동반한 고혈압 환자에서 장기간(>5년) 혈압강하 효과 입증[2]
- 한국 환자*를 대상으로 실시한 FOCUS study를 통해, 단독 및 병용 요법 모두에서 우수한 혈압조절 효과 입증[3]

*저용량 항고혈압제 단독요법으로 혈압조절이 어려운 고혈압 환자

아달라트® 오로스정

[제품명] 아달라트 오로스정 30/60 **[주성분]** 30: 1정(297.2mg) 중 니페디핀(미분화) 33mg, 60: 1정(562.9mg) 중 니페디핀(미분화) 66mg **[효능·효과]** 1. 관동맥심질환(만성안정형협심증) 2. 고혈압 **[용법·용량]** 처음에는 30mg 또는 60mg을 하루 한번씩 통상 7-14일간 투여하면서 환자의 상태에 따라 용량을 조절한다. 고혈압: 치료 시작시에 20mg이나 30mg을 권장한다. 약물의 혈중 농도가 둘째날부터 안정상태에 도달하므로 환자의 상황을 자주 측정하여 적정기간을 단축할 수 있다. 최고 120mg을 초과하지 않도록 한다. 반드시 환자의 증상에 따라서 조절되어야 한다. 삼투압 원리의 약물방출기전(오로스제형)을 이용하는 이 약의 투여는 식사와 무관하게 할 수 있다(공복시 또는 식사후의 이 약의 흡수에 차이는 없다). **[사용상의 주의사항]** 1. 다음 환자에는 투여하지 말 것 1) 이 약에 과민증의 병력이 있는 환자 2) 임부 또는 임신하고 있을 가능성이 있는 부인, 수유부 3) 심인성 속 환자 4) 불안정형 협심증 환자 (단, 제품의 효능·효과가 "협심증" 및 "휴식시의 협심증"에 해당되는 제제인 경우 제외) 5) 저혈압 (수축기압 90mmHg 미만) 환자 6) 중증의 대동맥판협착증 환자 7) 리팜피신을 투여받고 있는 환자 8) 급성 심근경색 (8일 이내) 환자 9) 직장절제수술 후 회장조루술을 받은 콕남(Kock pouch)환자 2. 주요 이상반응 1) 간장 : 때때로 AST, ALT, ALP 상승등 간기능 검사치이상, 2) 비뇨기계 : 때때로 BUN 상승 3) 순환기계 : 때때로 흉통, 허혈성 동통 (특히 치료 초기나 용량증가시), 심근경색, 때때로 안면홍조, 열감, 심계항진, 혈압강하, 기립성 저혈압, 하지부종, 말초부종, 저혈압, 혈관확장 4) 정신신경계 : 때때로 두통, 두통, 어지러움, 권태감, 신경쇠약, 감각이상, 불쾌감 5) 소화기계 : 때때로 구역, 구토, 변비, 소화불량 6) 과민증 : 때때로 발진, 가려움 7) 피부 : 홍피증 (박리성피부염) 8) 골격근 : 때때로 하지경련 9) 구강 : 연용에 의해 치은비후 10) 전신 : 때때로 불편감, 부종, 복통, 하지통, 동통 11) 호흡기계 : 때때로 호흡곤란 **[전문의약품]** **[수입 및 판매자]** 바이엘코리아㈜ **[개정년월일]** 2017.07.03 **보다 자세한 사항은 제품설명서 전문 또는 바이엘 웹사이트, http://www.bayer.co.kr/를 참고하시기 바랍니다.**

Reference 1. Mancia G, Omboni S, Parati G; Investigators of the INSIGHT ABPM substudy, Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). *J Hypertens* 2002 Mar;20(3):545-53 2. Lubsen J, Wagener G, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. *J Hypertens* 2005 Mar;23(3):641-8 3.Park JB, Ha JW, Jung HO, Rhee MY; FOCUS investigators, Randomized trial comparing the effects of a low-dose combination of nifedipine GITS and valsartan versus high-dose monotherapy on central hemodynamics in patients with inadequately controlled hypertension: FOCUS study, Blood Press *Monit* 2014 Oct;19(5):294-301

Bayer

바이엘 코리아(주) 07071 서울특별시 동작구 보라매로 5길 23(신대방동 395-62) 삼성보라매 옴니타워 Tel 02-829-6600 http://www.bayer.co.kr | LKR.MKT.06.2018.10172

통풍 치료의 1st 선택제

페소린™정

(페북소스타트 40mg, 80mg)

- 급여인정범위[1]가 확대되어 1차 약제로 사용 가능합니다.
- 목표요산치(6.0mg/dL 미만) 도달율이 높습니다.
- Non-purine 구조로 AHS[2]의 위험성이 낮습니다.

1) 2016년 7월 1일 고시 제2016-110호 2) AHS : Allopurinol Hypersensitivity Syndrome

Treatment of Hyperuricemia in Gout

[Drug Information]

■ **성분 및 함량** : Febuxostat 40mg, 80mg ■ **분류** : 394 (통풍치료제) ■ **효능효과** : 통풍환자에서의 만성적 고요산혈증의 치료
■ **용법용량** : – 성인 : 1일 1회 식사와 관계없이 40~80mg 복용 – 경증 및 중등도 신장애 및 간장애 환자 : 용량조절 필요없음
■ **KD Code** : – 40mg : 647804300 – 80mg : 647804290 *소비자상담전화 : 080-082-1234(수신자부담) www.samjinpharm.co.kr

SAMJIN 삼진제약(주)

KSN 2019

SEOUL, KOREA MAY 23 - 26

The 39th Annual Meeting of the Korean Society of Nephrology

Seoul Dragon City, Seoul, Korea

"Peaceful Kidneys, Save Lives"

KSN 2020

The 40th Annual Meeting of the Korean Society of Nephrology

May 14 (Thu) - 17 (Sun), 2020
Seoul, Korea

KSN 2019 Secretariat InSession International Convention Services, Inc.
4Fl. 10, Yeoksam-ro 7-gil, Gangnam-Gu, Seoul, 06244, Korea
Tel. +82-2-538-4603 **Fax.** +82-2-521-8683 **E-mail.** office@ksnmeeting.kr

ISSN: 2635-5051